Home The Word Brain	My Amedeo FAQ Privacy About
	Amedeo C49 English + 你好 (nǐ hǎo) = limitless possibilities. Start learning Mandarin Chinese today—for free, forever. Amedeo C49 is completely free, for life. Next week: +49.

Dermatology

Free Subscription Articles published in Br J Dermatol Retrieve available abstracts of 547 articles: HTML format

Single Articles

October 2025
1. LIPNICK MS, Chen D, Law T, Moore K Jr, et al
   Comparison of methods for characterizing skin pigment diversity in research cohorts.
   Br J Dermatol. 2025 Oct 10:ljaf397. doi: 10.1093.
   PubMed     Abstract available
   
   
   
2. HO G, Smith AL, Collgros H, Sinz C, et al
   Clinician and patient perspectives on implementation of a remote interpretation model of reflectance confocal microscopy for skin cancer diagnosis: a qualitative study using an acceptability framework.
   Br J Dermatol. 2025 Oct 9:ljaf348. doi: 10.1093.
   PubMed    
   
   
   
3. WEHKAMP U, Assaf C
   Primary cutaneous CD4(+) small/medium T-cell lymphoproliferative disorder - a truly "benign" disease?
   Br J Dermatol. 2025 Oct 5:ljaf389. doi: 10.1093.
   PubMed    
   
   
   
4. WRIGHT AK, Swan R, Xu J, Lwin SM, et al
   Skin disease in the Eastern Cape (SKINSCAPE): a Global Psoriasis Atlas point prevalence study in rural South Africa.
   Br J Dermatol. 2025 Oct 3:ljaf386. doi: 10.1093.
   PubMed     Abstract available
   
   
   
5. SVEDBOM A
   Potential additional benefits of glucagon-like peptide-1 receptor agonists in psoriasis.
   Br J Dermatol. 2025 Oct 1:ljaf382. doi: 10.1093.
   PubMed    
   
   
   September 2025
6. KEDDIE SH, Griffiths CEM, Jemec GBE, Ezzedine K, et al
   Grand Challenges for Skin Health Revisited: The International League of Dermatological Societies (ILDS) Skin Disease Atlases.
   Br J Dermatol. 2025 Sep 30:ljaf358. doi: 10.1093.
   PubMed    
   
   
   
7. FISCHER GM, Fang R, Xu S, Karkempetzaki AI, et al
   Loss of TET2 Facilitates Aggressive Behavior in Cutaneous Melanoma by Inducing PGC1alpha/Oxidative Phosphorylation (OXPHOS).
   Br J Dermatol. 2025 Sep 27:ljaf378. doi: 10.1093.
   PubMed     Abstract available
   
   
   
8. AFTAB Y, Moloney S, Ho B, Raymond B, et al
   Four decades of stagnation: A qualitative exploration of the lived experience of Atopic Dermatitis across ethnically and sexually diverse adults in the United Kingdom.
   Br J Dermatol. 2025 Sep 26:ljaf377. doi: 10.1093.
   PubMed    
   
   
   
9. DRUCKER AM, Williams E, Kaffenberger B, Dodiuk-Gad RP, et al
   Long-term morbidity and quality of life among survivors of Stevens-Johnson syndrome/toxic epidermal necrolysis spectrum.
   Br J Dermatol. 2025 Sep 26:ljaf380. doi: 10.1093.
   PubMed    
   
   
   
10. WANG SP, Myers E, Arents BWM, Flohr C, et al
    Caution regarding interpretation of trends for the global burden of atopic dermatitis and asthma.
    Br J Dermatol. 2025 Sep 26:ljaf369. doi: 10.1093.
    PubMed    
    
    
    
11. YIU ZZN
    Previous ineligibility for or treatment failure of ciclosporin does not influence lebrikizumab efficacy in atopic dermatitis.
    Br J Dermatol. 2025 Sep 23:ljaf316. doi: 10.1093.
    PubMed    
    
    
    
12. WARREN RB, de Bruin-Weller M, Tsianakas A, Khemis A, et al
    Efficacy and safety of lebrikizumab in adult and adolescent patients with moderate-to-severe atopic dermatitis inadequately controlled with or ineligible for ciclosporin A: a placebo-controlled, randomized phase IIIb clinical study (ADvantage).
    Br J Dermatol. 2025 Sep 22:ljaf285. doi: 10.1093.
    PubMed     Abstract available
    
    
    
13. FOSTER EL, Davis MI, Li AX, Kottner J, et al
    Identification of key symptoms for a core outcome set for research in vulvar lichen sclerosus: a CORALS symptom domain initiative.
    Br J Dermatol. 2025 Sep 22:ljaf374. doi: 10.1093.
    PubMed     Abstract available
    
    
    
14. TAN W, Chen Z, Xu M, Chen J, et al
    Single-cell RNA sequencing reveals transcriptomic landscape and potential targets for large/giant congenital melanocytic nevi.
    Br J Dermatol. 2025 Sep 20:ljaf360. doi: 10.1093.
    PubMed     Abstract available
    
    
    
15. MAI JZ, Kitahara CM, Sargen MR, Little MP, et al
    Residential ambient ultraviolet B and ultraviolet A and incidence of keratinocyte carcinoma in the nationwide US Radiologic Technologists cohort.
    Br J Dermatol. 2025;193:678-686.
    PubMed     Abstract available
    
    
    
16. HODAK E, Amitay-Laish I, Bagot M, Battistella M, et al
    ISCL/EORTC-CLTG/USCLC recommendations for the diagnosis, staging and treatment of early-stage paediatric mycosis fungoides: a modified Delphi consensus. Part two: treatment.
    Br J Dermatol. 2025;193:653-661.
    PubMed     Abstract available
    
    
    
17. JOPP H, Kraft A, Hoffmann B, Merkel R, et al
    Preclinical validation of PKC412 as a therapy candidate for epidermolysis bullosa simplex across multiple keratin pathogenic variants.
    Br J Dermatol. 2025;193:741-757.
    PubMed     Abstract available
    
    
    
18. AKIYAMA M, Choate K, Hernandez-Martin A, Aldwin-Easton M, et al
    Nonsyndromic epidermal differentiation disorders: a new classification toward pathogenesis-based therapy.
    Br J Dermatol. 2025;193:619-641.
    PubMed     Abstract available
    
    
    
19. PALLER AS, Teng J, Mazereeuw-Hautier J, Hernandez-Martin A, et al
    Syndromic epidermal differentiation disorders: a new classification toward pathogenesis-based therapy.
    Br J Dermatol. 2025;193:592-618.
    PubMed     Abstract available
    
    
    
20. ZHANG L, Wang M, Zhang L, Liang Y, et al
    Efficacy and Safety of Pumecitinib Gel for Treating Mild-to-moderate Atopic Dermatitis: a Multicentre, Randomised, Double-blind, Parallel, Placebo-controlled Phase IIb Clinical Trial.
    Br J Dermatol. 2025 Sep 18:ljaf363. doi: 10.1093.
    PubMed     Abstract available
    
    
    
21. FOSTER J, Sarlashkar P, Lu G, Teske N, et al
    Disparities in online patient education materials for rheumatic skin diseases.
    Br J Dermatol. 2025 Sep 15:ljaf371. doi: 10.1093.
    PubMed    
    
    
    
22. WHITEMAN DC
    BRAF testing for melanoma in England.
    Br J Dermatol. 2025 Sep 12:ljaf373. doi: 10.1093.
    PubMed    
    
    
    
23. AHMED S, van Bodegraven B, Proby C, Harwood CA, et al
    Ethnicity and the epidemiology of skin cancer incidence: a national retrospective population-based study in England, 2013-20.
    Br J Dermatol. 2025 Sep 10:ljaf352. doi: 10.1093.
    PubMed     Abstract available
    
    
    
24. SAMOTIJ D, Reich A
    Could TYK2 inhibition be a breakthrough in the effective treatment of cutaneous lupus erythematosus?
    Br J Dermatol. 2025 Sep 9:ljaf357. doi: 10.1093.
    PubMed    
    
    
    
25. BASHALL SEL, Thomas BR, Sim V, Wain M, et al
    Primary Cutaneous CD4+ Small Medium T Cell Lymphoproliferative Disorder - 20 years of experience from a specialist centre.
    Br J Dermatol. 2025 Sep 8:ljaf338. doi: 10.1093.
    PubMed     Abstract available
    
    
    
26. BOULANGER KP, McCuaig C, Roy AA, Kokta V, et al
    Striking improvement with targeted therapy in an ALK-positive atypical giant congenital melanocytic naevus of the right lower limb: a case report.
    Br J Dermatol. 2025 Sep 8:ljaf334. doi: 10.1093.
    PubMed    
    
    
    
27. WANG Y, Xin X, Xu Z
    Primary Annular Psoriasis.
    Br J Dermatol. 2025 Sep 5:ljaf340. doi: 10.1093.
    PubMed    
    
    
    
28. GHOSH S, Pavlova O, Latshaw A, Kim D, et al
    Multi-Harmonic Imaging-Based Automated Recognition of Cutaneous T-Cell Lymphoma.
    Br J Dermatol. 2025 Sep 4:ljaf345. doi: 10.1093.
    PubMed     Abstract available
    
    
    
29. HAFERKAMP S, Schilling B, Berking C, Drexler K, et al
    Breaking primary checkpoint inhibitor resistance with intermittent alkylating chemotherapy in patients with metastatic melanoma - Results of a multicenter phase II study.
    Br J Dermatol. 2025 Sep 4:ljaf350. doi: 10.1093.
    PubMed     Abstract available
    
    
    
30. MISTRY K, Jeffrey P, Levell NJ, Kennedy O, et al
    A national cohort study of melanoma BRAF status, testing patterns, patient and tumour characteristics, treatment and survival in England 2016-21.
    Br J Dermatol. 2025 Sep 3:ljaf351. doi: 10.1093.
    PubMed     Abstract available
    
    
    
31. LIU Z, Zheng DQ, Fan YM
    Recurrent eczematous dermatitis in a port-wine stain: Meyerson phenomenon.
    Br J Dermatol. 2025 Sep 3:ljaf342. doi: 10.1093.
    PubMed    
    
    
    
32. OLBRICH H, Kridin K, Zirpel H, Hernandez G, et al
    GLP-1RA and reduced mortality, cardiovascular and psychiatric risks in psoriasis: a large-scale cohort study.
    Br J Dermatol. 2025 Sep 3:ljaf346. doi: 10.1093.
    PubMed     Abstract available
    
    
    
33. TENG YS, Wang HJ
    Kaposi varicelliform eruption.
    Br J Dermatol. 2025 Sep 2:ljaf343. doi: 10.1093.
    PubMed    
    
    
    
34. ZHANG J, Silverberg JI, Guo J, Yun J, et al
    Rademikibart monotherapy for moderate-to-severe atopic dermatitis in a 1-year, randomized, phase II trial (SEASIDE CHINA): initial two-week dosing, followed by two-week or four-week dosing.
    Br J Dermatol. 2025 Sep 2:ljaf347. doi: 10.1093.
    PubMed     Abstract available
    
    
    August 2025
35. GU Y, Zhang B
    Stink bug-induced cutaneous chromatosis.
    Br J Dermatol. 2025 Aug 29:ljaf336. doi: 10.1093.
    PubMed    
    
    
    
36. REICH K, Langley RG, Salvador JFS, Staumont-Salle D, et al
    Safety of tralokinumab in patients with moderate-to-severe atopic dermatitis followed for up to 4.5 years: an integrated analysis of 8 clinical trials.
    Br J Dermatol. 2025 Aug 29:ljaf309. doi: 10.1093.
    PubMed     Abstract available
    
    
    
37. STEIN GOLD L, Gottlieb AB, Armstrong AW, Alkousakis T, et al
    SPECTREM Phase 3b Clinical Trial Results Through Week 16: Guselkumab Efficacy and Safety for the Treatment of Low Body Surface Area, Moderate Psoriasis With High-Impact Site Involvement.
    Br J Dermatol. 2025 Aug 28:ljaf327. doi: 10.1093.
    PubMed     Abstract available
    
    
    
38. XU YN, Pu M, Raut J, Du Y, et al
    Skin microbiome as a signature of premature ageing appearance: Manipulation through by use of topical products.
    Br J Dermatol. 2025 Aug 27:ljaf098. doi: 10.1093.
    PubMed     Abstract available
    
    
    
39. MAUBEC E
    Avelumab plus cetuximab in advanced cutaneous squamous cell carcinoma: a strategy to overcome resistance to PD-1 blockade.
    Br J Dermatol. 2025 Aug 21:ljaf331. doi: 10.1093.
    PubMed    
    
    
    
40. MOSS C
    Dermatitis artefacta explains haematohidrosis.
    Br J Dermatol. 2025 Aug 21:ljaf329. doi: 10.1093.
    PubMed    
    
    
    
41. MATSUDA KM, Harada T, Doi M, Io T, et al
    An open-label randomized parallel-group phase I study of the oral Bruton tyrosine kinase inhibitor tirabrutinib in systemic sclerosis.
    Br J Dermatol. 2025;193:434-441.
    PubMed     Abstract available
    
    
    
42. CHUNG HY, Chen CB, Lee HE, Lu CW, et al
    Janus kinase/signal transducer and activator of transcription signalling pathway is involved in the immune mechanism of bullous pemphigoid.
    Br J Dermatol. 2025;193:521-531.
    PubMed     Abstract available
    
    
    
43. HODAK E, Amitay-Laish I, Bagot M, Battistella M, et al
    ISCL/EORTC-CLTG/USCLC recommendations for the diagnosis, staging and treatment of early-stage paediatric mycosis fungoides: a modified Delphi consensus. Part one: diagnosis and staging.
    Br J Dermatol. 2025;193:405-414.
    PubMed     Abstract available
    
    
    
44. EL HACHEM M, Caldaro T, Lara-Corrales I, Pope E, et al
    Management of oesophageal strictures in inherited epidermolysis bullosa: a clinical practice guideline.
    Br J Dermatol. 2025;193:394-404.
    PubMed     Abstract available
    
    
    
45. CHRISTOU E, Lalagianni N, McSweeney SM, Cotter C, et al
    Psychosocial burden and the impact of illness perceptions and stigma on quality of life, anxiety and depression in alopecia areata: results from the Alopecia + Me study.
    Br J Dermatol. 2025;193:458-467.
    PubMed     Abstract available
    
    
    
46. MALOVITSKI K, Feller Y, Giladi M, Janagond AB, et al
    Loss-of-function variants in DUSP1 encoding dual specificity phosphatase 1 cause palmoplantar keratoderma.
    Br J Dermatol. 2025;193:532-543.
    PubMed     Abstract available
    
    
    
47. FUCHS M, Mochel M, Radeva MY, Schmitt T, et al
    Direct inhibition precedes p38 mitogen activated protein kinase-mediated uncoupling in desmosomes to reduce desmoglein 3 adhesion by pemphigus autoantibodies.
    Br J Dermatol. 2025;193:468-479.
    PubMed     Abstract available
    
    
    
48. QIAN Q, Gu Y, Luo J, Wu S, et al
    Genetic and environmental factors affecting hair density in East Asian populations.
    Br J Dermatol. 2025;193:502-513.
    PubMed     Abstract available
    
    
    
49. BONE M, Schreyer D, Treanor-Taylor M, Proby CM, et al
    The landscape of long noncoding RNA during cutaneous squamous cell carcinoma progression.
    Br J Dermatol. 2025;193:490-501.
    PubMed     Abstract available
    
    
    
50. SPRECHER E, Ishida-Yamamoto A, Schwartz J, Akiyama M, et al
    Palmoplantar epidermal differentiation disorders: a new classification toward pathogenesis-based therapy.
    Br J Dermatol. 2025;193:364-380.
    PubMed     Abstract available
    
    
    
51. BABER C, Busch L, Klein AL, Infante VHP, et al
    Mechanistic in vivo studies of secondary skin-to-skin peanut allergen transfer to determine the impact of hand washing in reducing the risk of cutaneous sensitization.
    Br J Dermatol. 2025 Aug 16:ljaf214. doi: 10.1093.
    PubMed     Abstract available
    
    
    
52. SHIMOMURA Y
    Unravelling the molecular basis for premature diffuse familial sebaceous hyperplasia.
    Br J Dermatol. 2025 Aug 12:ljaf320. doi: 10.1093.
    PubMed    
    
    
    
53. WASSERER S, Seiringer P, Kurzen N, Jargosch M, et al
    TYK2 inhibition improves clinical and molecular hallmarks in various subtypes of cutaneous lupus.
    Br J Dermatol. 2025 Aug 8:ljaf293. doi: 10.1093.
    PubMed     Abstract available
    
    
    
54. WILLEMZE R, Assaf C, Bagot M, Beylot-Barry M, et al
    EORTC/USCLC/ISCL consensus recommendations for management and treatment of cutaneous lymphoproliferative disorders.
    Br J Dermatol. 2025 Aug 6:ljaf312. doi: 10.1093.
    PubMed     Abstract available
    
    
    July 2025
55. PALLER AS, Fiorillo L, Becker E, Armesto S, et al
    Efficacy and safety of apremilast in pediatric patients with moderate to severe plaque psoriasis: 52-week results from the SPROUT randomized controlled trial.
    Br J Dermatol. 2025 Jul 30:ljaf305. doi: 10.1093.
    PubMed     Abstract available
    
    
    
56. KELLY ASV, Moustaqim-Barrette A, Xie C, Shah A, et al
    Under the arctic sun: assessment of skin cancer risk and sun protection behaviors in Indigenous communities in Nunavik, an emerging at-risk population for skin cancers.
    Br J Dermatol. 2025 Jul 30:ljaf290. doi: 10.1093.
    PubMed    
    
    
    
57. BECKER JC, Gesierich AH, Leiter U, Zimmer L, et al
    Avelumab plus cetuximab in patients with unresectable stage III or IV cutaneous squamous cell carcinoma - clinical activity and safety results from AliCe, a single-arm, multicentre phase 2 DeCOG trial.
    Br J Dermatol. 2025 Jul 26:ljaf303. doi: 10.1093.
    PubMed     Abstract available
    
    
    
58. LIANG L, Wang S, Huang S, Sun Y, et al
    A gain-of-function variant in NNT causes premature diffuse familial sebaceous hyperplasia.
    Br J Dermatol. 2025 Jul 25:ljaf294. doi: 10.1093.
    PubMed     Abstract available
    
    
    
59. FOLKMANN CL, Pinborg EH, Iversen M, Ronnstad ATM, et al
    The association between hidradenitis suppurativa and psychiatric disease: a systematic review and meta-analysis.
    Br J Dermatol. 2025;193:212-220.
    PubMed     Abstract available
    
    
    
60. HIEL MAJ, Korte EWH, Tedbirt B, Bolling MC, et al
    Outcome measurement in pemphigus clinical research: a scoping review on heterogeneity in outcome reporting and definitions.
    Br J Dermatol. 2025;193:221-231.
    PubMed     Abstract available
    
    
    
61. TORRELO A, Colmenero I, Alvarez-Twose I
    Childhood mastocytosis: challenges and potential shortfalls in current disease classification.
    Br J Dermatol. 2025;193:203-211.
    PubMed     Abstract available
    
    
    
62. HUANG Z, Zhao W, Xu C, Zheng J, et al
    Interleukin (IL)-34 promotes the inflammatory role of IL-1beta-producing myeloid cells in pemphigus lesions.
    Br J Dermatol. 2025;193:287-297.
    PubMed     Abstract available
    
    
    
63. NOCK MR, Griffiths D, Shields A, Michael K, et al
    Measurement properties of the Comprehensive Quality-of-Life Measure for Acne (CompAQ): a cohort study at three international sites.
    Br J Dermatol. 2025;193:267-275.
    PubMed     Abstract available
    
    
    
64. MOSTAGHIMI A, Craiglow B, King B, Shapiro J, et al
    Understanding eyebrow and eyelash involvement in patients with alopecia areata and responsiveness to treatment with baricitinib.
    Br J Dermatol. 2025;193:240-249.
    PubMed     Abstract available
    
    
    
65. PARAGH G, Huss WJ
    Shedding new light on narrowband ultraviolet B phototherapy: balancing psoriasis treatment and carcinogenic risk.
    Br J Dermatol. 2025 Jul 16:ljaf218. doi: 10.1093.
    PubMed    
    
    
    
66. KWATRA SG, Pereira MP, Misery L, Mollanazar NK, et al
    Prurigo nodularis: disease burden, clinical features and approach to management.
    Br J Dermatol. 2025 Jul 16:ljaf213. doi: 10.1093.
    PubMed     Abstract available
    
    
    
67. CREAMER D
    Quality of life assessment in Stevens-Johnson syndrome / toxic epidermal necrolysis (SJS/TEN): damage assessment guides damage limitation.
    Br J Dermatol. 2025 Jul 15:ljaf278. doi: 10.1093.
    PubMed    
    
    
    
68. LIU D, Hu BD, Mishra A, Patel D, et al
    Tape Strips in Inflammatory Skin Disease: A Noninvasive Method for Molecular Insights and Personalized Care.
    Br J Dermatol. 2025 Jul 14:ljaf275. doi: 10.1093.
    PubMed     Abstract available
    
    
    
69. NARDIN C, Cavalieri C, Lebbe C, Gerard E, et al
    Neoadjuvant immune checkpoint inhibitors for patients with resectable stage III/IV melanoma: A nationwide real-life study in France (NEOMEL).
    Br J Dermatol. 2025 Jul 14:ljaf268. doi: 10.1093.
    PubMed     Abstract available
    
    
    
70. EPSTEIN Z, Epstein L, Rork J, Koo J, et al
    Skin Picking in Down syndrome: A Patient Speaks Out.
    Br J Dermatol. 2025 Jul 7:ljaf264. doi: 10.1093.
    PubMed    
    
    
    
71. KARPONIS D, Mistry K, Stratigos G, Levell NJ, et al
    Can the effects of the COVID-19 pandemic provide insights into the impact of melanoma under-diagnosis and delayed care?
    Br J Dermatol. 2025 Jul 3:ljaf263. doi: 10.1093.
    PubMed    
    
    
    
72. PAPADAVID E, Scarisbrick J
    The critical role of National Referral Centers of excellence in the accurate diagnosis and management of Cutaneous Lymphomas.
    Br J Dermatol. 2025 Jul 3:ljaf256. doi: 10.1093.
    PubMed    
    
    
    June 2025
73. AFACH S, Sbidian E
    Hormonal therapy and psoriasis risk: a new concern for women's health?
    Br J Dermatol. 2025 Jun 30:ljaf261. doi: 10.1093.
    PubMed    
    
    
    
74. KRISTYANTO H, Rey Torre S, Cunney A, Dunder K, et al
    The European Medicines Agency evaluation of nemolizumab (Nemluvio) for the treatment of moderate-to-severe atopic dermatitis and prurigo nodularis.
    Br J Dermatol. 2025 Jun 28:ljaf259. doi: 10.1093.
    PubMed    
    
    
    
75. DOUSSET L, Khalife F, Chalopin-Fillot D, Dartigues B, et al
    Metabolism-based scoring of cutaneous squamous cell carcinoma to predict tumor features and responses to treatment by DHODH inhibitors.
    Br J Dermatol. 2025 Jun 27:ljaf253. doi: 10.1093.
    PubMed     Abstract available
    
    
    
76. CAI ZR, Kim J, Rezaei SJ, Chen ML, et al
    Assessing the Performance of Artificial Intelligence Models in Evaluating Inflammatory Skin Disease Severity: A Systematic Review and Meta-Analysis.
    Br J Dermatol. 2025 Jun 26:ljaf250. doi: 10.1093.
    PubMed     Abstract available
    
    
    
77. BAI X, Flaherty KT
    The Rise of New Targets in Melanoma.
    Br J Dermatol. 2025 Jun 26:ljaf251. doi: 10.1093.
    PubMed     Abstract available
    
    
    
78. SEXTON F, O' Mahony J, Sumera S, Golchin R, et al
    Culprit allergens in diabetes technology-associated allergic contact dermatitis: investigation remains challenging.
    Br J Dermatol. 2025 Jun 26:ljaf245. doi: 10.1093.
    PubMed    
    
    
    
79. IMHOF RL, Yang E, Lehman J, Tekin B, et al
    Lichen planus pemphigoides - A retrospective single-center cohort over two decades and comparison of idiopathic vs. drug-induced cases.
    Br J Dermatol. 2025 Jun 25:ljaf240. doi: 10.1093.
    PubMed    
    
    
    
80. LEE EY, Ang YS, Leow SY, Koh MJA, et al
    Mobile Inpatient Care at Home: A Pilot Programme for Paediatric Patients with Atopic Dermatitis in Singapore.
    Br J Dermatol. 2025 Jun 24:ljaf246. doi: 10.1093.
    PubMed    
    
    
    
81. LIU T, Chang JM
    Clown Nose-Like Cutaneous Metastasis.
    Br J Dermatol. 2025 Jun 24:ljaf247. doi: 10.1093.
    PubMed    
    
    
    
82. ALANI O, Ahmed A, Haraldsdottir EL, Hoyt D, et al
    The Incidence and Impact of Melanoma Subtypes in Iceland 1955-2023.
    Br J Dermatol. 2025 Jun 23:ljaf248. doi: 10.1093.
    PubMed    
    
    
    
83. GOODERHAM M, Torres T, Imafuku S, Rademaker M, et al
    Efficacy and Safety of Upadacitinib Dose Escalation and Reduction in Adult Patients With Moderate-To-Severe Atopic Dermatitis: Results of a Randomized, Blinded, Treat-To-Target, Multicenter Phase 3b/4 Study (Flex Up).
    Br J Dermatol. 2025 Jun 23:ljaf236. doi: 10.1093.
    PubMed     Abstract available
    
    
    
84. O'REILLY P, Savarimalai R, Walsh S, Barry LA, et al
    The impact of Stevens-Johnson syndrome (SJS) and toxic epidermal necrolysis (TEN) on the health-related quality of life (HRQoL) experiences of adults with SJS/TEN: A mixed method systematic review.
    Br J Dermatol. 2025 Jun 21:ljaf229. doi: 10.1093.
    PubMed     Abstract available
    
    
    
85. YUAN Y, Wang H, Pan M, Zheng J, et al
    Exome and transcriptome analysis link calcium channel pathway aberrations to botulinum toxin A resistance in Hailey-Hailey disease.
    Br J Dermatol. 2025;193:147-156.
    PubMed     Abstract available
    
    
    
86. KIRBY JS, Thorlacius L, Lambert J, Ciaravino V, et al
    Psychometric validation and interpretation thresholds of the Hidradenitis Suppurativa Quality of Life (HiSQOL(c)) questionnaire using pooled data from the phase III BE HEARD I & II trials of bimekizumab in hidradenitis suppurativa.
    Br J Dermatol. 2025;193:93-104.
    PubMed     Abstract available
    
    
    
87. YOKOZEKI H, Murota H, Matsumura T
    Long-term (68 weeks) administration of nemolizumab and topical corticosteroids for prurigo nodularis in patients aged >/= 13 years: efficacy and safety data from a phase II/III study.
    Br J Dermatol. 2025;193:56-65.
    PubMed     Abstract available
    
    
    
88. HOWELLS L, Leighton P, Thomas KS, Collier F, et al
    A qualitative interview study exploring patients' views and experiences of treatment for hidradenitis suppurativa in the UK.
    Br J Dermatol. 2025;193:85-92.
    PubMed     Abstract available
    
    
    
89. GAY-MIMBRERA J, Lozano-Ojalvo D, Gomez-Arias PJ, Rivera-Ruiz I, et al
    Comprehensive single-cell chromatin and transcriptomic profiling of peripheral immune cells in nonsegmental vitiligo.
    Br J Dermatol. 2025;193:115-124.
    PubMed     Abstract available
    
    
    
90. CHANG CY, Chan K, Chen HC, Lai CC, et al
    Atopic dermatitis epidemiological research methodology: a global scoping review.
    Br J Dermatol. 2025 Jun 19:ljaf238. doi: 10.1093.
    PubMed     Abstract available
    
    
    
91. KAHLER S, Primiero C, Jayasinghe D, Mothershaw A, et al
    Unpredictable interdependence of invasive and in situ melanoma.
    Br J Dermatol. 2025 Jun 19:ljaf235. doi: 10.1093.
    PubMed    
    
    
    
92. TAN JY, Marlow L, Phillips C, McPherson T, et al
    Chronic inflammatory skin conditions in adolescents and their impact on intimate relationships - a quantitative and qualitative study.
    Br J Dermatol. 2025 Jun 13:ljaf228. doi: 10.1093.
    PubMed     Abstract available
    
    
    
93. XIAO H, Ding Y, Shen M, Chen X, et al
    Menopausal Age, Hormone Therapy, and Risk of Psoriasis: A Prospective Cohort Study applying Inverse Probability of Treatment Weighting Analysis.
    Br J Dermatol. 2025 Jun 10:ljaf222. doi: 10.1093.
    PubMed    
    
    
    
94. SIA T, Li S, Zhong X, Park C, et al
    Acitretin chemoprevention in non-melanoma skin cancer patients with chronic hematopoietic disease: findings from three independent databases.
    Br J Dermatol. 2025 Jun 10:ljaf221. doi: 10.1093.
    PubMed    
    
    
    
95. LIU Z, Zhang Y, Wang K, Xie F, et al
    Early diagnosis model of mycosis fungoides and five inflammatory skin diseases based on multi-modal data-based convolutional neural network.
    Br J Dermatol. 2025 Jun 4:ljaf212. doi: 10.1093.
    PubMed     Abstract available
    
    
    
96. LIU X, McBride JD
    Unmethylated PRAME DNA in Tissue and Plasma: A Promising Marker for Melanoma.
    Br J Dermatol. 2025 Jun 3:ljaf217. doi: 10.1093.
    PubMed    
    
    
    
97. DANESH K, Adler BL, Vecerek N
    Toxic epidermal necrolysis-like acute cutaneous lupus erythematosus.
    Br J Dermatol. 2025 Jun 3:ljaf215. doi: 10.1093.
    PubMed    
    
    
    May 2025
98. BRUSTAD N, Wang T, Chen L, Kaiser H, et al
    Prenatal high-dose vitamin D supplementation and childhood atopic dermatitis until age 6 years: A secondary analysis of a randomized clinical trial.
    Br J Dermatol. 2025 May 30:ljaf208. doi: 10.1093.
    PubMed    
    
    
    
99. BOOSTANI M, Wortsman X, Pellacani G, Cantisani C, et al
    Dermoscopy-guided high-frequency ultrasound for preoperative assessment of basal cell carcinoma lateral margins: A pilot study.
    Br J Dermatol. 2025 May 29:ljaf209. doi: 10.1093.
    PubMed    
    
    
    
100. LAIMER M, South AP, Mayr E, Kitzmueller S, et al
     Efficacy and Safety of Rigosertib in Patients with Recessive Dystrophic Epidermolysis Bullosa Associated Advanced/Metastatic Cutaneous Squamous Cell Carcinoma.
     Br J Dermatol. 2025 May 29:ljaf205. doi: 10.1093.
     PubMed     Abstract available
     
     
     
101. TYSON-CARR J, Leng J, Scott M, Adams S, et al
     Body-site specific associations between human skin microbiome composition and psychological wellbeing.
     Br J Dermatol. 2025 May 26:ljaf177. doi: 10.1093.
     PubMed     Abstract available
     
     
     
102. GARGIULO L, Costanzo A
     Age of Onset Matters: Tildrakizumab Response in Early vs Late-Onset Psoriasis.
     Br J Dermatol. 2025 May 23:ljaf186. doi: 10.1093.
     PubMed    
     
     
     
103. MCGRATH JA, Mellerio JE
     The classification of Ichthyosis morphs into Epidermal Differentiation Disorders.
     Br J Dermatol. 2025 May 23:ljaf197. doi: 10.1093.
     PubMed    
     
     
     
104. LEE JYW, Mahil SK
     Systemic inflammation and psoriasis: unpicking a complex relationship.
     Br J Dermatol. 2025 May 23:ljaf203. doi: 10.1093.
     PubMed    
     
     
     
105. ANDREW PV, Williams SF, Brown K, Chittock J, et al
     Topical supplementation with physiologic lipids rebalances the stratum corneum ceramide profile and strengthens skin barrier function in adults predisposed to atopic dermatitis.
     Br J Dermatol. 2025 May 23:ljaf200. doi: 10.1093.
     PubMed     Abstract available
     
     
     
106. MAHO-VAILLANT M, Lemieux A, Arnoult C, Lebourgeois L, et al
     Prevalence and pathogenic activity of anti-desmocollin-3 antibodies in patients with pemphigus vulgaris and pemphigus foliaceus.
     Br J Dermatol. 2025;192:1072-1082.
     PubMed     Abstract available
     
     
     
107. KIM BR, Kim G, Jin SP, Choi CW, et al
     Causal association between polyunsaturated fatty acids and acne: a two-sample Mendelian randomization study.
     Br J Dermatol. 2025;192:1106-1114.
     PubMed     Abstract available
     
     
     
108. MURRELL DF, Bodemer C, Bruckner AL, Cunningham T, et al
     Long-term safety and efficacy of Oleogel-S10 (birch bark extract) in epidermolysis bullosa: 24-month results from the phase III EASE study.
     Br J Dermatol. 2025;192:1007-1017.
     PubMed     Abstract available
     
     
     
109. APFELBACHER C, Bewley A, Molin S, Fargnoli MC, et al
     Prevalence of chronic hand eczema in adults: a cross-sectional survey of over 60 000 respondents from the general population of Canada, France, Germany, Italy, Spain and the UK.
     Br J Dermatol. 2025;192:1047-1054.
     PubMed     Abstract available
     
     
     
110. DIMITRION PM, Krevh R, Veenstra J, Ge J, et al
     High-throughput proteomics identifies inflammatory proteins associated with disease severity and genetic ancestry in patients with hidradenitis suppurativa.
     Br J Dermatol. 2025;192:1063-1071.
     PubMed     Abstract available
     
     
     
111. POWELL JB, Dhesi JK, Harwood CA, McGrath EJ, et al
     How do we avoid over-treating skin cancer in people with severe frailty and limited life expectancy?
     Br J Dermatol. 2025 May 15:ljaf174. doi: 10.1093.
     PubMed    
     
     
     
112. DA ROSA GP, Santos JV, Cerejeira A, Matos P, et al
     Patterns of hospitalizations due to bacterial skin and soft tissue infections: a retrospective observational study from a Portuguese national registry.
     Br J Dermatol. 2025 May 15:ljaf157. doi: 10.1093.
     PubMed    
     
     
     
113. DOELEMAN T, Beljaards ESM, Ottevanger R, Jansen P, et al
     Added value of pathology consultations in cutaneous lymphomas: a 2-year review from the Dutch national referral and expertise centre.
     Br J Dermatol. 2025 May 14:ljaf184. doi: 10.1093.
     PubMed     Abstract available
     
     
     
114. CHEN JQ, Zheng M, Yin WH, Wang P, et al
     Safety and efficacy of the selective TYK2/JAK1 inhibitor TLL-018 in moderate-to-severe plaque psoriasis: A phase 1b, randomized, double-blind, placebo-controlled study.
     Br J Dermatol. 2025 May 14:ljaf185. doi: 10.1093.
     PubMed     Abstract available
     
     
     
115. ARMSTRONG AW, Blauvelt A, Lebwohl M, Asahina A, et al
     Efficacy and safety of tildrakizumab in patients with early- vs late-onset psoriasis.
     Br J Dermatol. 2025 May 14:ljaf171. doi: 10.1093.
     PubMed     Abstract available
     
     
     
116. YANG HW, Chen YH, To SY, Wen YL, et al
     Hormone Therapy and Increased Risk of Psoriasis in Reproductive-age and Postmenopausal Women: A Nationwide Cohort Study and Target Trial Emulation.
     Br J Dermatol. 2025 May 9:ljaf179. doi: 10.1093.
     PubMed     Abstract available
     
     
     
117. WANG Y, Xu G, Xia H
     Targeting the MAPK Pathway for NRAS Mutant Melanoma: From Mechanism to Clinic.
     Br J Dermatol. 2025 May 9:ljaf178. doi: 10.1093.
     PubMed     Abstract available
     
     
     
118. DRUCKER AM, Walwyn C, Chu C, Yiu ZZN, et al
     Living network meta-analysis to compare nemolizumab against other available targeted systemic treatments for atopic dermatitis.
     Br J Dermatol. 2025 May 7:ljaf166. doi: 10.1093.
     PubMed    
     
     
     
119. WHITEMAN DC
     Melanoma in England: incidence is up, mortality is down.
     Br J Dermatol. 2025 May 7:ljaf175. doi: 10.1093.
     PubMed    
     
     
     
120. MORTIMORE AM, McMeniman E
     Reassuring results from skin cancer risk in Swedish patients with vitiligo and alopecia areata.
     Br J Dermatol. 2025 May 6:ljaf118. doi: 10.1093.
     PubMed    
     
     
     
121. FOWLER JC, Sood RK, Coltart G, Lai C, et al
     The mutation burden of narrowband ultraviolet B phototherapy (NB-UVB) in human skin; relevance to NB-UVB lifetime exposures and skin cancer surveillance.
     Br J Dermatol. 2025 May 3:ljaf173. doi: 10.1093.
     PubMed     Abstract available
     
     
     
122. KIRCIK L, Tsianakas A, Valenzuela F, Mikol V, et al
     Efficacy and Safety of Rilzabrutinib in Patients With Moderate-to-Severe Atopic Dermatitis: 16-Week Results From a Proof-of-Concept Phase II Clinical Trial.
     Br J Dermatol. 2025 May 3:ljaf156. doi: 10.1093.
     PubMed     Abstract available
     
     
     
123. ZHANG WW, Ke LF, Chen Y, Wu CY, et al
     Methylation-Based Test for Diagnosis of Benign and Malignant Melanocytoma.
     Br J Dermatol. 2025 May 2:ljaf169. doi: 10.1093.
     PubMed     Abstract available
     
     
     
124. GILLESPIE J, Bash GN, Jacobson ME, Latour E, et al
     Harmonizing Measurement of Eczema Control- Mapping Scores Between the Atopic Dermatitis Control Tool and The Recap of Atopic Eczema Instrument.
     Br J Dermatol. 2025 May 2:ljaf167. doi: 10.1093.
     PubMed     Abstract available
     
     
     
125. LU G, Chambers S, Cepica T, Xie L, et al
     Erythema and scale in cutaneous lupus erythematosus significantly impacts patient quality of life and disease course impression.
     Br J Dermatol. 2025 May 2:ljaf165. doi: 10.1093.
     PubMed    
     
     
     April 2025
126. JIANG X, Mortlock RD, Lomakin IB, Zhou J, et al
     Autosomal dominant SLURP1 variants cause palmoplantar keratoderma and progressive symmetric erythrokeratoderma.
     Br J Dermatol. 2025;192:896-906.
     PubMed     Abstract available
     
     
     
127. PATHMARAJAH P, Eid E, Nazaroff J, So J, et al
     Functional genotype classification groups distinguish disease severity in recessive dystrophic epidermolysis bullosa.
     Br J Dermatol. 2025;192:917-925.
     PubMed     Abstract available
     
     
     
128. SCHELL SL, Sennett ML, Feehan RP, Wallace TE, et al
     Pilot study of topical ruxolitinib demonstrates efficacy and blunting of heterogeneous inflammatory processes in mild hidradenitis suppurativa.
     Br J Dermatol. 2025;192:845-856.
     PubMed     Abstract available
     
     
     
129. LIU Y, Liu Z, Li D, He X, et al
     Emerging role of regulatory T cells in the immunopathogenesis of vitiligo and implications for treatment.
     Br J Dermatol. 2025;192:796-806.
     PubMed     Abstract available
     
     
     
130. SILVERBERG JI, Dodiuk-Gad R, Takaoka R, Tan J, et al
     Atopic dermatitis starting in childhood has a stronger impact on adults: results from the "Scars of Life" international project in 27 countries.
     Br J Dermatol. 2025 Apr 26:ljaf158. doi: 10.1093.
     PubMed    
     
     
     
131. LEMARCQ L, Reynaert V, Van den Steen E, Evers-Lebrun C, et al
     Outcome Measures for Interdisciplinary Care in Immune-mediated Inflammatory Skin Diseases (skIMIDs): A Scoping Review.
     Br J Dermatol. 2025 Apr 18:ljaf153. doi: 10.1093.
     PubMed     Abstract available
     
     
     
132. NASLUND-KOCH C, Kvist-Hansen A, Bojesen SE, Skov L, et al
     Low-grade systemic inflammation is associated with risk of psoriasis in a general population study of more than 100,000 individuals.
     Br J Dermatol. 2025 Apr 18:ljaf147. doi: 10.1093.
     PubMed     Abstract available
     
     
     
133. DUGOURD PM, Guardoli D, Fontas E, Marie-Luce S, et al
     Promoting Repigmentation after Epidermal cell suspension grafting and preVENTing the loss of melanocytes using topical ruxolitinib for vitiligo in resistant areas (PREVENT). A prospective monocentric interventional double-blind study.
     Br J Dermatol. 2025 Apr 17:ljaf143. doi: 10.1093.
     PubMed    
     
     
     
134. FARIYIKE O, Johnson NA, Van Bodegraven B, Quirke K, et al
     The role of limited life expectancy in personalised treatment decisions: 1 in 6 patients aged 80+ with a basal cell carcinoma die within 2 years of diagnosis in England.
     Br J Dermatol. 2025 Apr 15:ljaf135. doi: 10.1093.
     PubMed    
     
     
     
135. ZHU J, Abuabara K
     Complex comorbidities: Could a diabetes drug help prevent atopic dermatitis?
     Br J Dermatol. 2025 Apr 15:ljaf131. doi: 10.1093.
     PubMed    
     
     
     
136. CHEN J, Liu X, Bai Y, Tang X, et al
     Tonsillar Microbiota Alterations Contribute to Immune Responses in Psoriasis by Skewing Aged Neutrophils.
     Br J Dermatol. 2025 Apr 15:ljaf134. doi: 10.1093.
     PubMed     Abstract available
     
     
     
137. KARPONIS D, van Bodegraven B, Mistry K, Nikolaou V, et al
     Incidence and mortality of melanoma in situ and malignant melanoma in England between 2001 and 2020.
     Br J Dermatol. 2025 Apr 15:ljaf136. doi: 10.1093.
     PubMed     Abstract available
     
     
     
138. PILERI A, Zengarini C
     Harnessing Extracorporeal Photopheresis to Trigger Immunogen Cell Death: A Bounty on Cutaneous Lymphoma Cells.
     Br J Dermatol. 2025 Apr 12:ljaf138. doi: 10.1093.
     PubMed    
     
     
     
139. HUAI P, Xing P, Yang Y, Kong Y, et al
     Global burden of skin and subcutaneous diseases: an update from the Global Burden of Disease Study 2021.
     Br J Dermatol. 2025 Apr 11:ljaf071. doi: 10.1093.
     PubMed    
     
     
     
140. FALTOT L, Donzel M, Chidiac G, Balme B, et al
     Evaluation of the anti-CCR4 monoclonal antibody Mogamulizumab in advanced cutaneous T-cell lymphomas and with large cell transformation.
     Br J Dermatol. 2025 Apr 7:ljaf125. doi: 10.1093.
     PubMed    
     
     
     
141. MAZEREEUW-HAUTIER J, Paller AS, O'Toole E, Dreyfus I, et al
     Management of congenital ichthyoses: Guidelines of care: Part Two: 2024 Update.
     Br J Dermatol. 2025 Apr 7:ljaf077. doi: 10.1093.
     PubMed     Abstract available
     
     
     
142. WANG J, Hennessey D, Iyer A, O'Keefe S, et al
     Transcriptomic skin niches in systemic sclerosis underpins a role for mitochondrial dysfunction.
     Br J Dermatol. 2025 Apr 2:ljaf119. doi: 10.1093.
     PubMed    
     
     
     
143. ISKANDAR RJ, Tadrous M, Nguyen P, Dolovich L, et al
     Characteristics of patients seeking skin-related minor ailment pharmacy services in Ontario, Canada: A population-based cross-sectional study.
     Br J Dermatol. 2025 Apr 2:ljaf092. doi: 10.1093.
     PubMed    
     
     
     
144. SARASWAT N, Tripathy DM, Adhau RW, Tripathy A, et al
     Furuncular Myiasis in the skin of colour.
     Br J Dermatol. 2025 Apr 1:ljaf114. doi: 10.1093.
     PubMed    
     
     
     March 2025
145. MAZEREEUW-HAUTIER J, Paller AS, Dreyfus I, Sprecher E, et al
     Management of congenital ichthyoses: Guidelines of care: Part One: 2024 Update.
     Br J Dermatol. 2025 Mar 28:ljaf076. doi: 10.1093.
     PubMed     Abstract available
     
     
     
146. ALEXANDER H, Murryam S, Kezic S, Motazedi E, et al
     Methotrexate and Cyclosporin Improve Skin Biomarkers in Paediatric Atopic Dermatitis: Results from the TREatment of Severe Atopic Eczema Trial.
     Br J Dermatol. 2025 Mar 27:ljaf115. doi: 10.1093.
     PubMed    
     
     
     
147. VESTERGAARD C
     Air Pollution and Atopic Dermatitis: Critical Windows of Risk in Early Life.
     Br J Dermatol. 2025 Mar 24:ljaf109. doi: 10.1093.
     PubMed    
     
     
     
148. BAGOT M
     Therapeutic advances for Cutaneous T Cell Lymphoma.
     Br J Dermatol. 2025 Mar 22:ljaf105. doi: 10.1093.
     PubMed     Abstract available
     
     
     
149. LACKNER A, Burner T, Brandner M, Dey S, et al
     Evidence of Immunogenic Cell Death (ICD) and ICD-dependent Dendritic Cell Activation Induced by Extracorporeal Photopheresis in Patients with leukemic forms of cutaneous T cell lymphoma.
     Br J Dermatol. 2025 Mar 20:ljaf102. doi: 10.1093.
     PubMed     Abstract available
     
     
     
150. LEE CN, Hsieh MH, Chen CY, Yang CC, et al
     Risk of Herpes Zoster and Postherpetic Neuralgia in Patients with Psoriasis Treated with Biologics: A nationwide study using target trial emulation framework.
     Br J Dermatol. 2025 Mar 20:ljaf101. doi: 10.1093.
     PubMed     Abstract available
     
     
     
151. DE LA IGLESIA MARTIN J, Martin Vera J, Tubau Prims C
     Dermatitis cruris pustulosa et atrophicans.
     Br J Dermatol. 2025 Mar 20:ljaf103. doi: 10.1093.
     PubMed    
     
     
     
152. AHMADY S, Mosterd K, Jansen MHE, Kelleners-Smeets NWJ, et al
     Patient preferences for the treatment of Bowen disease.
     Br J Dermatol. 2025;192:653-659.
     PubMed     Abstract available
     
     
     
153. KIMBALL AB, Bechara FG, Badat A, Giamarellos-Bourboulis EJ, et al
     Long-term efficacy and safety of secukinumab in patients with moderate-to-severe hidradenitis suppurativa: week 104 results from the SUNSHINE and SUNRISE extension trial.
     Br J Dermatol. 2025;192:629-640.
     PubMed     Abstract available
     
     
     
154. LEAR JT, Harwood CA, Hasan Z, Kentley J, et al
     Topical application of the Hedgehog inhibitor patidegib in patients with Gorlin syndrome: a phase II trial.
     Br J Dermatol. 2025;192:611-617.
     PubMed     Abstract available
     
     
     
155. RASTRICK J, Edwards H, Ferecsko AS, Le Friec G, et al
     The roles of interleukin (IL)-17A and IL-17F in hidradenitis suppurativa pathogenesis: evidence from human in vitro preclinical experiments and clinical samples.
     Br J Dermatol. 2025;192:660-671.
     PubMed     Abstract available
     
     
     
156. HUA VK, Chang J, Laxer RM, Broderick L, et al
     Disabling pansclerotic morphoea: a century of discovery.
     Br J Dermatol. 2025;192:585-596.
     PubMed     Abstract available
     
     
     
157. WALBURN J, Norton S, Sarkany R, Canfield M, et al
     A personalized and systematically designed adherence intervention improves photoprotection in adults with xeroderma pigmentosum (XP): results of the XPAND randomized controlled trial.
     Br J Dermatol. 2025;192:728-737.
     PubMed     Abstract available
     
     
     
158. NAKAMIZO S, Kabashima K
     Cutaneous Granulomas: Mechanisms, Cellular Interactions, and Therapeutic Insights.
     Br J Dermatol. 2025 Mar 13:ljaf096. doi: 10.1093.
     PubMed     Abstract available
     
     
     
159. MIRANDA BH, Shahid S, Correiro A, Zhang J, et al
     St Andrews Referral Delay in Skin Cancer (StARDISC): A study of keratinocyte skin cancer time to treatment, growth, invasiveness, British Association of Dermatologists risk factors and excision adequacy.
     Br J Dermatol. 2025 Mar 13:ljaf097. doi: 10.1093.
     PubMed     Abstract available
     
     
     
160. LI T, Tao R, Yang L, Wan Z, et al
     Upadacitinib outperforms dupilumab in restoring the fungal microbiome in atopic dermatitis.
     Br J Dermatol. 2025 Mar 12:ljaf095. doi: 10.1093.
     PubMed    
     
     
     
161. SU T, Yu Y, Su Z, Lu Y, et al
     Rapid improvements in Kaposi sarcoma with metformin: a report of two cases.
     Br J Dermatol. 2025 Mar 11:ljaf090. doi: 10.1093.
     PubMed    
     
     
     
162. ZHANG Q, Liu G, Jing L, Aghayants S, et al
     The Landscape of m6A RNA Methylation in Skin Diseases.
     Br J Dermatol. 2025 Mar 10:ljaf087. doi: 10.1093.
     PubMed     Abstract available
     
     
     
163. WEN YL, Hsu WT, Chen YH, Kao HH, et al
     Sodium-glucose Cotransporter 2 Inhibitors and Inverse Risk of New-onset Atopic Dermatitis in Diabetic Population: a Nationwide, Active-comparator Study.
     Br J Dermatol. 2025 Mar 4:ljaf086. doi: 10.1093.
     PubMed     Abstract available
     
     
     
164. KOCHI Y, Togawa Y, Yamazaki Y, Yamamoto Y, et al
     Anatomical distribution of acral lentiginous melanoma in the hand and nail among Japanese individuals.
     Br J Dermatol. 2025 Mar 4:ljaf070. doi: 10.1093.
     PubMed    
     
     
     
165. VON SCHUCKMANN LA, Khosrotehrani K
     Haematological cancers and skin cancer: statistics from the Netherlands.
     Br J Dermatol. 2025 Mar 1:ljaf081. doi: 10.1093.
     PubMed    
     
     
     February 2025
166. COSTANZA M, Giordano C, von Brunneck AC, Zhao J, et al
     Preclinical in vitro and in vivo evidence for CD74-targeting as effective treatment strategy for cutaneous T cell lymphomas.
     Br J Dermatol. 2025 Feb 27:ljaf001. doi: 10.1093.
     PubMed     Abstract available
     
     
     
167. ACKERMANN DM, Bell KJL
     Setting the melanoma research agenda for all end-users: the need to include patient, clinician, and policy perspectives.
     Br J Dermatol. 2025 Feb 27:ljaf082. doi: 10.1093.
     PubMed    
     
     
     
168. NARDIN C, Vernerey D, Aubin F
     Ipilimumab + nivolumab combination or nivolumab monotherapy as first-line treatment in patients with metastatic melanoma: conclusions from a real-world French national cohort.
     Br J Dermatol. 2025 Feb 27:ljaf080. doi: 10.1093.
     PubMed    
     
     
     
169. MISTRY K, Srimudkul O, Patel M, Ragan J, et al
     Patient research priorities in melanoma: a national qualitative interview study.
     Br J Dermatol. 2025 Feb 27:ljaf048. doi: 10.1093.
     PubMed     Abstract available
     
     
     
170. ROY SF, Agim NG, Mir A, Couts KL, et al
     Congenital melanocytic nevi initiated by BRAF fusion oncogene with firmness, pruritus, and desmoplastic stroma.
     Br J Dermatol. 2025 Feb 27:ljaf061. doi: 10.1093.
     PubMed     Abstract available
     
     
     
171. LIN LH, Lee CC, Hwang MM, Jung CR, et al
     Fine particulate matter exposure and incident atopic dermatitis: A birth cohort study.
     Br J Dermatol. 2025 Feb 26:ljaf075. doi: 10.1093.
     PubMed     Abstract available
     
     
     
172. KROAH-HARTMAN M, Lee JYW, Dooley N, Tan WR, et al
     Environmental triggers of psoriasis: insights from a UK patient-reported cohort (mySkin).
     Br J Dermatol. 2025 Feb 25:ljaf073. doi: 10.1093.
     PubMed    
     
     
     
173. DELCOIGNE B, Lysell J, Askling J
     Incidence, stage and outcome of melanoma, keratinocyte and other cancers in individuals with vitiligo or alopecia: intraindividual or familial risks?
     Br J Dermatol. 2025 Feb 25:ljaf074. doi: 10.1093.
     PubMed     Abstract available
     
     
     
174. OTTEVANGER R, Vermeer MH
     Cutaneous T-cell lymphoma in Australia: what drives geospatial?
     Br J Dermatol. 2025 Feb 22:ljaf026. doi: 10.1093.
     PubMed    
     
     
     
175. WANG Z, Liu J, Wechsberg O, Liang L, et al
     Variants in KLF4 affecting residue Asp441 cause an autosomal dominant syndromic ichthyosis.
     Br J Dermatol. 2025 Feb 19:ljaf062. doi: 10.1093.
     PubMed     Abstract available
     
     
     
176. PERIS K
     Patidegib: a novel, promising treatment for basal cell carcinoma lesions in patients with Gorlin syndrome.
     Br J Dermatol. 2025 Feb 19:ljae515. doi: 10.1093.
     PubMed    
     
     
     
177. GNIADECKI R, Guenova E, Querfeld C, Nicolay JP, et al
     Haematogenous seeding in mycosis fungoides and Sezary syndrome: current evidence and clinical implications.
     Br J Dermatol. 2025;192:381-389.
     PubMed     Abstract available
     
     
     
178. PHILIPP-DORMSTON WG, Bruckner M, Hoffmann M, Bae M, et al
     Artificial daylight photodynamic therapy using methyl aminolaevulinate in a real-world setting in Germany: results from the noninterventional study ArtLight.
     Br J Dermatol. 2025;192:510-519.
     PubMed     Abstract available
     
     
     
179. WEHKAMP U, Pietzka S, Kotrova M, Jost M, et al
     Mycosis fungoides: differentiation from inflammation and detection of circulating tumour cells with the EuroClonality next-generation sequencing assay.
     Br J Dermatol. 2025;192:492-500.
     PubMed     Abstract available
     
     
     
180. DONHAUSER T, Gabes M, Masur C, Kamudoni P, et al
     Longitudinal validity of the Hyperhidrosis Quality of Life Index (HidroQoL(c)) in a phase IIIb clinical trial population with hyperhidrosis: responsiveness and meaningful change.
     Br J Dermatol. 2025;192:450-457.
     PubMed     Abstract available
     
     
     
181. SWIDERSKI M, Vinogradova Y, Knaggs RD, Harman K, et al
     Association between drugs and vaccines commonly prescribed to older people and bullous pemphigoid: a case-control study.
     Br J Dermatol. 2025;192:440-449.
     PubMed     Abstract available
     
     
     
182. KIM SR, Koh SJ, Park H
     Association of childhood obesity or weight change with early-onset follicular occlusion triad in children.
     Br J Dermatol. 2025;192:430-439.
     PubMed     Abstract available
     
     
     
183. PLANELLA-FONTANILLAS N, Bosch-Amate X, Jimenez Anton A, Moreno-Vilchez C, et al
     Real-world evaluation of the effectiveness and safety of dupilumab in bullous pemphigoid: an ambispective multicentre case series.
     Br J Dermatol. 2025;192:501-509.
     PubMed     Abstract available
     
     
     
184. SZONDI DC, Crompton RA, Oon L, Subramaniam N, et al
     A role for Arginase in skin epithelial differentiation and anti-microbial peptide production.
     Br J Dermatol. 2025 Feb 14:ljaf057. doi: 10.1093.
     PubMed     Abstract available
     
     
     
185. ZOUBOULIS CC, Deloche C, Skayem C, Leclerc-Mercier S, et al
     Global study of 17,009 women reveal significant skin condition changes associated with irregular menstrual cycles.
     Br J Dermatol. 2025 Feb 11:ljae484. doi: 10.1093.
     PubMed    
     
     
     
186. LOPEZ S, Thakker S, Minkis K
     Beyond the Diagnosis: A Skin of Color Patient's Journey with Acral Lentiginous Melanoma.
     Br J Dermatol. 2025 Feb 6:ljaf047. doi: 10.1093.
     PubMed    
     
     
     
187. VON KOBYLETZKI L, Svensson A
     Patient-reported outcome measures are highly needed for patients with skin of colour with atopic dermatitis.
     Br J Dermatol. 2025 Feb 4:ljaf043. doi: 10.1093.
     PubMed    
     
     
     
188. FREW JW
     Unravelling the complex pathogenesis of hidradenitis suppurativa.
     Br J Dermatol. 2025;192.
     PubMed     Abstract available
     
     
     
189. PETUKHOVA L, Colvin A, Koerts NDK, Horvath B, et al
     Leveraging genotypes and phenotypes to implement precision medicine in hidradenitis suppurativa management.
     Br J Dermatol. 2025;192.
     PubMed     Abstract available
     
     
     
190. SAYED CJ, Shams RB, Midgette B, Garg A, et al
     An evolutionary tale on clinical trials in hidradenitis suppurativa.
     Br J Dermatol. 2025;192.
     PubMed     Abstract available
     
     
     January 2025
191. LEDUCQ S, Fong WCG, Williams HC, Bradshaw L, et al
     Reporting of concomitant and rescue topical therapies in atopic dermatitis randomised controlled trials evaluating a systemic treatment: a scoping review.
     Br J Dermatol. 2025 Jan 30:ljaf031. doi: 10.1093.
     PubMed     Abstract available
     
     
     
192. ALVES C
     Orismilast for moderate-to-severe atopic dermatitis: the potential therapeutic value of a new oral pharmacological alternative.
     Br J Dermatol. 2025 Jan 30:ljaf042. doi: 10.1093.
     PubMed    
     
     
     
193. GNIADECKI R
     Chaperoning a Cure: Unexpected Role of CD74 in Cutaneous T-cell lymphoma.
     Br J Dermatol. 2025 Jan 29:ljaf040. doi: 10.1093.
     PubMed    
     
     
     
194. KANEDA E, Koguchi-Yoshioka H, Nimura K, Hattori S, et al
     Genotype-phenotype correlation for skin and neuropsychiatric features in tuberous sclerosis complex.
     Br J Dermatol. 2025 Jan 28:ljaf038. doi: 10.1093.
     PubMed    
     
     
     
195. WARREN RB, Lebwohl M, Thaci D, Gooderham M, et al
     Bimekizumab efficacy and safety through 3 years in patients with moderate to severe plaque psoriasis: Long-term results from the BE RADIANT phase 3b trial open-label extension period.
     Br J Dermatol. 2025 Jan 25:ljaf032. doi: 10.1093.
     PubMed     Abstract available
     
     
     
196. PILIANG M, Soung J, King B, Shapiro J, et al
     Efficacy and safety of the oral Janus kinase 3/tyrosine kinase expressed in hepatocellular carcinoma family kinase inhibitor ritlecitinib over 24 months: integrated analysis of the ALLEGRO phase IIb/III and long-term phase III clinical studies in alop
     Br J Dermatol. 2025;192:215-227.
     PubMed     Abstract available
     
     
     
197. GARG A, Burge R, Cohee A, Wallinger H, et al
     Validation of the real-world application of the Hidradenitis Suppurativa Quality of Life (HiSQOL) score to adults with hidradenitis suppurativa.
     Br J Dermatol. 2025;192:261-268.
     PubMed     Abstract available
     
     
     
198. ZHU Z, Zhong X, Luo Z, Liu M, et al
     Global, regional and national burdens of acne vulgaris in adolescents and young adults aged 10-24 years from 1990 to 2021: a trend analysis.
     Br J Dermatol. 2025;192:228-237.
     PubMed     Abstract available
     
     
     
199. PERALS C, le Jan S, Muller C, Le Naour R, et al
     Polarization of circulating follicular helper T cells correlates with bullous pemphigoid severity.
     Br J Dermatol. 2025;192:283-292.
     PubMed     Abstract available
     
     
     
200. EGGERMONT CJ, Hollatz A, Wakkee M, Louwman M, et al
     Skin cancer risk in over 200.000 patients with haematologic malignancies in 30 years; a nationwide population-based study in the Netherlands.
     Br J Dermatol. 2025 Jan 24:ljaf027. doi: 10.1093.
     PubMed     Abstract available
     
     
     
201. 
     Correction to: Microbiome characterization of skin biopsies in Spanish patients with hidradenitis suppurativa shows a decrease in D1 and H1 lineages of Cutibacterium acnes.
     Br J Dermatol. 2025 Jan 24:ljaf029. doi: 10.1093.
     PubMed    
     
     
     
202. BARKER JN, Casanova E, Choon SE, Foley P, et al
     Global Delphi consensus on treatment goals for generalised pustular psoriasis.
     Br J Dermatol. 2025 Jan 23:ljae491. doi: 10.1093.
     PubMed     Abstract available
     
     
     
203. SMITH MJ, Peach H, Keohane S, Lear J, et al
     Melanoma: Assessment and Management summary of 2022 update of the NICE guidelines.
     Br J Dermatol. 2025 Jan 21:ljaf016. doi: 10.1093.
     PubMed     Abstract available
     
     
     
204. ANDERSON ADG, Shirwac HF, Morgan H, Greenish H, et al
     Real-World Melanoma Miss-Rate In An NHS Hospital Dermatology Service. A Retrospective Study.
     Br J Dermatol. 2025 Jan 16:ljaf024. doi: 10.1093.
     PubMed    
     
     
     
205. ALABAS OA, Mason KJ, Yiu ZZN, Smith CH, et al
     Age and biologic survival in patients with moderate-to-severe psoriasis: A cohort study from the British Association of Dermatologists Biologics and Immunomodulators Register (BADBIR).
     Br J Dermatol. 2025 Jan 10:ljaf017. doi: 10.1093.
     PubMed     Abstract available
     
     
     
206. HARTFORD C, Alexis A, Wang Z, Levit NA, et al
     Development of novel patient-reported outcome instruments to assess atopic dermatitis-associated dyspigmentation and xerosis in patients with skin of colour.
     Br J Dermatol. 2025 Jan 10:ljae494. doi: 10.1093.
     PubMed     Abstract available
     
     
     
207. PUIG L
     Post-switching discontinuation of biosimilars in psoriasis: registry analyses fall short in addressing real-world biases.
     Br J Dermatol. 2025 Jan 7:ljaf003. doi: 10.1093.
     PubMed    
     
     
     
208. CHENG JW, Li JH
     Squamous cell carcinoma arising from lichen planus.
     Br J Dermatol. 2025 Jan 7:ljaf007. doi: 10.1093.
     PubMed    
     
     
     
209. MCGRATH JA, Kabashima K
     Unlocking the skin's immunological secrets: antibodies and new topical vaccination strategies.
     Br J Dermatol. 2025 Jan 7:ljaf014. doi: 10.1093.
     PubMed    
     
     
     
210. SILVERBERG JI, Eichenfield LF, Blauvelt A, Irvine AD, et al
     Orismilast, a PDE4B/D inhibitor, in moderate-to-severe atopic dermatitis: Efficacy and safety from a multicenter, randomized, placebo-controlled, phase 2b dose-ranging study (ADESOS).
     Br J Dermatol. 2025 Jan 7:ljae507. doi: 10.1093.
     PubMed     Abstract available
     
     
     December 2024
211. PLACKE JM, Bottek J, Varaljai R, Shannan B, et al
     Spatial proteomics reveals sirtuin 1 to be a determinant of T-cell infiltration in human melanoma.
     Br J Dermatol. 2024 Dec 31:ljae433. doi: 10.1093.
     PubMed     Abstract available
     
     
     
212. PATRA V, Wolf P
     Skin microbiome and polymorphous light eruption.
     Br J Dermatol. 2024 Dec 26:ljae513. doi: 10.1093.
     PubMed    
     
     
     
213. TAKASE K, Komatsu-Fujii T, Kogame T, Otsuka A, et al
     Tinea corporis at the injection site of interleukin-17 inhibitor in psoriasis vulgaris.
     Br J Dermatol. 2024 Dec 26:ljae511. doi: 10.1093.
     PubMed    
     
     
     
214. CHEN Z, Wang Y, Wang R
     Generalized granulomatous slack skin.
     Br J Dermatol. 2024 Dec 25:ljae508. doi: 10.1093.
     PubMed    
     
     
     
215. CARRASCOSA JM
     Optimizing dosing in atopic dermatitis therapy: Looking for the cream of the crop.
     Br J Dermatol. 2024 Dec 25:ljae514. doi: 10.1093.
     PubMed    
     
     
     
216. IWASAWA O, Ikegami M, Miyagawa T, Morita H, et al
     Association of genetic alterations with prognosis in extramammary Paget disease: insights into the involvement of somatic CDKN2A variants in patients with a poor prognosis.
     Br J Dermatol. 2024;192:46-54.
     PubMed     Abstract available
     
     
     
217. BONTOUX C, Badrignans M, Afach S, Sbidian E, et al
     Pustular mycosis fungoides has a poor outcome: a multicentric clinicopathological and molecular case series.
     Br J Dermatol. 2024;192:125-134.
     PubMed     Abstract available
     
     
     
218. ELEFTHERIADOU V, Ahmed A, Nesnas J, Nagra R, et al
     The lifetime risk and impact of vitiligo across sociodemographic groups: a UK population-based cohort study.
     Br J Dermatol. 2024;192:63-71.
     PubMed     Abstract available
     
     
     
219. LI J, Wang Y, Niu X, Xing J, et al
     Downregulation of lysine 2-hydroxyisobutyrylation of ErbB3 binding protein 1 at amino acid 210 promotes keratinocyte proliferation via induction of transcription initiation factor IA-mediated rRNA synthesis.
     Br J Dermatol. 2024;192:92-103.
     PubMed     Abstract available
     
     
     
220. 
     Correction to: Severity rating of specific skin lesions in hidradenitis suppurativa: the patient perspective.
     Br J Dermatol. 2024 Dec 23:ljae474. doi: 10.1093.
     PubMed    
     
     
     
221. PRAJAPATI VH, Seyger MMB, Wilsmann-Theis D, Szakos E, et al
     Guselkumab for the treatment of moderate-to-severe plaque psoriasis in pediatric patients: results of the phase 3, randomized, placebo-controlled PROTOSTAR study.
     Br J Dermatol. 2024 Dec 21:ljae502. doi: 10.1093.
     PubMed     Abstract available
     
     
     
222. PREIS S, Biedermann T, Zink A
     Unseen Spaces: Psoriasis Inversa Between the Toes.
     Br J Dermatol. 2024 Dec 21:ljae500. doi: 10.1093.
     PubMed    
     
     
     
223. BADAWY H, Harvey J, Rajan N, Stuart B, et al
     Changes in skin research funding: the emergence of environmental sustainability criteria in the research competition assessment process.
     Br J Dermatol. 2024 Dec 20:ljae503. doi: 10.1093.
     PubMed    
     
     
     
224. CHEN L, Tan M, Li T, Zhu L, et al
     Rapid and sustained response of stubborn guttate psoriasis to ustekinumab: A 52-week, two-center, one-arm, observational study.
     Br J Dermatol. 2024 Dec 18:ljae481. doi: 10.1093.
     PubMed     Abstract available
     
     
     
225. WHITEMAN DC, Pandeya N, Olsen CM
     Differences in mean age at diagnosis of invasive melanoma for men and women, by anatomic site, thickness, and subtype.
     Br J Dermatol. 2024 Dec 17:ljae482. doi: 10.1093.
     PubMed     Abstract available
     
     
     
226. MITRA R, Hale TK, Fitzsimons HL, Gray C, et al
     A novel three-dimensional model of Infantile Haemangioma.
     Br J Dermatol. 2024 Dec 17:ljae483. doi: 10.1093.
     PubMed     Abstract available
     
     
     
227. LYNCH M
     Beyond the Algorithm: Ethical Challenges in AI-Driven Skin Cancer Diagnosis.
     Br J Dermatol. 2024 Dec 16:ljae490. doi: 10.1093.
     PubMed    
     
     
     
228. MORTATO E, Talamonti M, Paganini C, Belcastro A, et al
     Comment on "A Practical Guide to Using Oral JAK Inhibitors for Atopic Dermatitis from the International Eczema Council"- A case of Rhabdomyolysis Induced by Upadacitinib.
     Br J Dermatol. 2024 Dec 13:ljae485. doi: 10.1093.
     PubMed    
     
     
     
229. LOUVEAU B, Jouenne F, Ram-Wolff C, Mancini M, et al
     Comment on 'Oncogenic alterations in KIR3DL1 in cutaneous acral CD8+ lymphoproliferative disorder' by Wobser et al.
     Br J Dermatol. 2024 Dec 13:ljae487. doi: 10.1093.
     PubMed    
     
     
     
230. DOUSSET L, Khosrotehrani K
     A new frontier in drug discovery for skin cancer through electronic medical records.
     Br J Dermatol. 2024 Dec 13:ljae489. doi: 10.1093.
     PubMed    
     
     
     
231. BERESFORD-WYLIE B, Ashcroft S, Gaglani B, Green A, et al
     Integrating artificial intelligence into skin cancer pathways; the opportunities and obstacles.
     Br J Dermatol. 2024 Dec 11:ljae480. doi: 10.1093.
     PubMed    
     
     
     
232. CHO SI, Na JI
     Long-term observation to determine durable efficacy and safety of novel paediatric atopic dermatitis treatment, nemolizumab.
     Br J Dermatol. 2024 Dec 10:ljae479. doi: 10.1093.
     PubMed    
     
     
     
233. SINKKO H, Olah P, Yang Y, Maia G, et al
     Taxonomic and functional profiling of skin microbiome in psoriasis.
     Br J Dermatol. 2024 Dec 9:ljae471. doi: 10.1093.
     PubMed    
     
     
     
234. SHAH SFH, O'Toole EA
     Biologics in Congenital Ichthyosis - an Incomplete Fix.
     Br J Dermatol. 2024 Dec 6:ljae475. doi: 10.1093.
     PubMed    
     
     
     
235. CAMPBELL BA, Baade PD, Dasgupta P, Cameron JK, et al
     Geospatial analyses demonstrate variation of cutaneous T-cell lymphomas across Australia, providing insights into possible causes.
     Br J Dermatol. 2024 Dec 6:ljae476. doi: 10.1093.
     PubMed     Abstract available
     
     
     
236. WEIDINGER S, Bewley A, Hong HC, Silvestre JF, et al
     Predicting success with reduced dosing frequency of tralokinumab in patients with moderate-to-severe atopic dermatitis.
     Br J Dermatol. 2024 Dec 5:ljae439. doi: 10.1093.
     PubMed     Abstract available
     
     
     
237. MCGRATH JA
     Recently discovered roles for macrophages in human skin development.
     Br J Dermatol. 2024 Dec 4:ljae473. doi: 10.1093.
     PubMed    
     
     
     November 2024
238. IGARASHI A, Katsunuma T, Nagano Y, Komazaki H, et al
     Long-term (68 weeks) administration of nemolizumab in paediatric patients aged 6-12 years with atopic dermatitis with moderate-to-severe pruritus: efficacy and safety data from a phase III study.
     Br J Dermatol. 2024 Nov 28:ljae458. doi: 10.1093.
     PubMed     Abstract available
     
     
     
239. KARINE B, Mortier L, Dereure O, Dalac S, et al
     The efficacy and safety of first-line metastatic melanoma treatment with ipilimumab + nivolumab versus nivolumab in a real-world setting.
     Br J Dermatol. 2024 Nov 28:ljae470. doi: 10.1093.
     PubMed     Abstract available
     
     
     
240. WOLBER AK, Jayasinghe D, Betz-Stablein B, Janda M, et al
     Incidence and patterns of newly developed pigmented lesions in adults at high risk for melanoma.
     Br J Dermatol. 2024 Nov 26:ljae467. doi: 10.1093.
     PubMed    
     
     
     
241. LI CY, Wang WT, Ma SH, Lo LW, et al
     Association of PCSK9 inhibitors with risk of nonmelanoma skin cancer: a retrospective cohort study.
     Br J Dermatol. 2024 Nov 25:ljae438. doi: 10.1093.
     PubMed     Abstract available
     
     
     
242. AMAR Y, Niedermeier S, Silva R, Kublik S, et al
     Skin microbiome dynamics in patients with polymorphic light eruption in response to UV radiations.
     Br J Dermatol. 2024 Nov 22:ljae464. doi: 10.1093.
     PubMed     Abstract available
     
     
     
243. ZHANG B, Mei J, Liao Q, Zhou S, et al
     Multitranscriptome analysis revealed that stromal cells in the papillary dermis promote angiogenesis in psoriasis vulgaris.
     Br J Dermatol. 2024 Nov 21:ljae459. doi: 10.1093.
     PubMed     Abstract available
     
     
     
244. PHAN DB, Jourdain H, Descalzo-Gallego MA, Gonzalez-Quesada A, et al
     Drug Survival and Safety of Biosimilars Compared with Originator Adalimumab for Psoriasis: A Multinational Cohort Study.
     Br J Dermatol. 2024 Nov 20:ljae454. doi: 10.1093.
     PubMed     Abstract available
     
     
     
245. THOMPSON AR, Tziotzios C, Nesnas J, Randall R, et al
     Lifetime incidence and healthcare disparities in alopecia areata: a UK population-based cohort study.
     Br J Dermatol. 2024;191:924-935.
     PubMed     Abstract available
     
     
     
246. XIONG X, Cesarato N, Gossmann Y, Wehner M, et al
     A nonsense variant in KRT31 is associated with autosomal dominant monilethrix.
     Br J Dermatol. 2024;191:979-987.
     PubMed     Abstract available
     
     
     
247. PATTINSON R, Trialonis-Suthakharan N, Pickles T, Austin J, et al
     Measurement properties and interpretability of the Patient-Reported Impact of Dermatological Diseases (PRIDD) measure.
     Br J Dermatol. 2024;191:936-948.
     PubMed     Abstract available
     
     
     
248. OUYANG F, Yang H, Di Z, Hu J, et al
     Life's Essential 8, genetic susceptibility and the risk of psoriatic disease: a prospective cohort study.
     Br J Dermatol. 2024;191:897-905.
     PubMed     Abstract available
     
     
     
249. SINGH N, Schikowski T
     Interactive effect of genetic and environmental risk factors on Psoriasis: current evidence and future directives.
     Br J Dermatol. 2024 Nov 15:ljae450. doi: 10.1093.
     PubMed    
     
     
     
250. ZHENG DX, Jenkins RW
     Real-world data confirms limited efficacy of dual anti-PD-1 and CTLA-4 immune checkpoint blockade in acral lentiginous melanoma.
     Br J Dermatol. 2024 Nov 15:ljae445. doi: 10.1093.
     PubMed    
     
     
     
251. 
     Correction to: COL10A1 expression distinguishes a subset of cancer-associated fibroblasts present in the stroma of high-risk basal cell carcinoma.
     Br J Dermatol. 2024 Nov 11:ljae440. doi: 10.1093.
     PubMed    
     
     
     
252. VAN DER WEYDEN L, Del Castillo Velasco-Herrera M, Cheema S, Wong K, et al
     Exploration of the mutational landscape of cutaneous leiomyoma confirms FH as a driver gene and identifies targeting purine metabolism as a potential therapeutic strategy.
     Br J Dermatol. 2024 Nov 7:ljae432. doi: 10.1093.
     PubMed    
     
     
     
253. VAN VEEN FCAP, Rossel SVJ, Steijlen PM, Moser A, et al
     The perceived quality of life in adult patients with inherited ichthyosis: a qualitative interview study.
     Br J Dermatol. 2024 Nov 7:ljae436. doi: 10.1093.
     PubMed    
     
     
     
254. SHAH SFH, Arecco D, Draper H, Tiribelli S, et al
     Ethical implications of artificial intelligence in skin cancer diagnostics: use-case analyses.
     Br J Dermatol. 2024 Nov 6:ljae434. doi: 10.1093.
     PubMed     Abstract available
     
     
     
255. CHIU TM, Chen CB, Lu CW, Hui RC, et al
     CCR8/CCL1 and CXCR3/CXCL10 axis mediated memory T cell activations in recalcitrant drug-induced hypersensitivity patients.
     Br J Dermatol. 2024 Nov 6:ljae375. doi: 10.1093.
     PubMed     Abstract available
     
     
     
256. TAYLOR MA, Yuan M, Wang S, North JP, et al
     A Case of Biologic-Resistant Hand Dermatitis Demonstrates Dual T2/T17 Transcriptomic Abnormalities and Responds to JAK Inhibition.
     Br J Dermatol. 2024 Nov 5:ljae430. doi: 10.1093.
     PubMed    
     
     
     
257. SANGERS TE, van Doorn R
     The usefulness of large language models for patient information on melanoma: challenges and opportunities.
     Br J Dermatol. 2024 Nov 1:ljae429. doi: 10.1093.
     PubMed    
     
     
     October 2024
258. WELLER RB, Gu J
     Ultraviolet radiation is not the major cause of melanoma mortality in the UK and sun exposure advice should be revised.
     Br J Dermatol. 2024 Oct 30:ljae426. doi: 10.1093.
     PubMed    
     
     
     
259. MAZEREEUW-HAUTIER J, Granier Tournier C, Hernandez-Martin A, Milesi S, et al
     Biologics in congenital ichthyosis: are they effective?
     Br J Dermatol. 2024 Oct 29:ljae420. doi: 10.1093.
     PubMed     Abstract available
     
     
     
260. RAUWERDINK DJW, Hoogland Y, Schrader AMR, Potjer TP, et al
     Melanoma arising from pre-existing naevus in carriers of a germline CDKN2A pathogenic variant.
     Br J Dermatol. 2024 Oct 29:ljae417. doi: 10.1093.
     PubMed    
     
     
     
261. CHEN M, Gao L
     Carcinoid syndrome presenting as diffuse violaceous cutaneous flushing.
     Br J Dermatol. 2024 Oct 26:ljae424. doi: 10.1093.
     PubMed    
     
     
     
262. BLAUVELT A, Papp K, Trivedi M, Barragan C, et al
     Efficacy and safety of the ustekinumab biosimilar ABP 654 in patients with moderate-to-severe plaque psoriasis: a randomized, double-blinded, active-controlled, comparative clinical study over 52 weeks.
     Br J Dermatol. 2024 Oct 23:ljae402. doi: 10.1093.
     PubMed     Abstract available
     
     
     
263. KATOH N, Tanaka A, Takahashi H, Shimizu R, et al
     Long-term management of moderate-to-severe atopic dermatitis with lebrikizumab and concomitant topical corticosteroids: a 68-week, randomized, double-blind, placebo-controlled phase III trial in Japan (ADhere-J).
     Br J Dermatol. 2024 Oct 23:ljae394. doi: 10.1093.
     PubMed     Abstract available
     
     
     
264. YANG X, Li L, Zhu M
     Primary cutaneous Alternaria alstroemeriae infection.
     Br J Dermatol. 2024 Oct 23:ljae409. doi: 10.1093.
     PubMed    
     
     
     
265. MCGILLIVRAY E, Ashouri K, Chatziioannou E, Gallegos JAO, et al
     Combined PD-1 and CTLA-4 Blockade in an International Cohort of Patients with Acral Lentiginous Melanoma.
     Br J Dermatol. 2024 Oct 23:ljae401. doi: 10.1093.
     PubMed     Abstract available
     
     
     
266. SILVERBERG JI, Bunick CG, Hong HC, Mendes-Bastos P, et al
     Efficacy and Safety of Upadacitinib vs Dupilumab in Adults and Adolescents with Moderate-to-Severe Atopic Dermatitis: Week 16 results of an Open-label, Randomized, Efficacy Assessor-Blinded Head-to-Head Phase 3b/4 Study (Level Up).
     Br J Dermatol. 2024 Oct 23:ljae404. doi: 10.1093.
     PubMed     Abstract available
     
     
     
267. ZHANG J, Ding Y, Wang P, Li L, et al
     Deucravacitinib, an oral, selective, allosteric tyrosine kinase 2 inhibitor, in patients from China mainland, Taiwan, and South Korea with moderate to severe plaque psoriasis: a phase 3 randomized clinical trial.
     Br J Dermatol. 2024 Oct 22:ljae406. doi: 10.1093.
     PubMed     Abstract available
     
     
     
268. BLANCHARD G, Atallah I, Blanchard M, Fehrenbacher B, et al
     Primary cutaneous T-cell lymphoma not otherwise specified (NOS) uncovering a novel RAB27A variant in Griscelli syndrome type 2.
     Br J Dermatol. 2024 Oct 21:ljae412. doi: 10.1093.
     PubMed    
     
     
     
269. BARBIERI JS
     Levelling up outcomes in atopic dermatitis through personalized dosing of upadacitinib.
     Br J Dermatol. 2024 Oct 19:ljae410. doi: 10.1093.
     PubMed    
     
     
     
270. KOBYLETZKI LBV, Svensson A
     Treatment for atopic dermatitis with JAK Inhibitors-useful recommendations from expert opinions.
     Br J Dermatol. 2024 Oct 19:ljae396. doi: 10.1093.
     PubMed    
     
     
     
271. WANG Q, Niu G, Liu Z, Toma MA, et al
     Circular RNA circASH1L(4,5) protects microRNA-129-5p from target-directed microRNA degradation in human skin wound healing.
     Br J Dermatol. 2024 Oct 18:ljae405. doi: 10.1093.
     PubMed     Abstract available
     
     
     
272. CAMPBELL C, Mayatra JM, Neve AJ, Fletcher JM, et al
     Inflammasomes: emerging therapeutic targets in hidradenitis suppurativa?
     Br J Dermatol. 2024;191:670-679.
     PubMed     Abstract available
     
     
     
273. KORTE EWH, Baardman R, Pool G, Duipmans JC, et al
     Navigating the diagnostic journey of epidermolysis bullosa: a qualitative study of the lived experiences and needs of parents and patients.
     Br J Dermatol. 2024;191:737-745.
     PubMed     Abstract available
     
     
     
274. TSENG H, Stone C, Shulruf B, Murrell DF, et al
     Establishing minimal clinically important differences for the Pemphigus Disease Area Index.
     Br J Dermatol. 2024;191:823-831.
     PubMed     Abstract available
     
     
     
275. SORENSEN SBT, Farkas DK, Vestergaard C, Schmidt SAJ, et al
     Urticaria and the risk of cancer: a Danish population-based cohort study.
     Br J Dermatol. 2024;191:706-712.
     PubMed     Abstract available
     
     
     
276. YOSIPOVITCH G, Skayem C, Aroman MS, Taieb C, et al
     International study on prevalence of itch: examining the role of itch as a major global public health problem.
     Br J Dermatol. 2024;191:713-718.
     PubMed     Abstract available
     
     
     
277. RUTKOWSKI D, Scholey R, Davies J, Pye D, et al
     Epidermal growth factor receptor/mitogen-activated kinase inhibitor treatment induces a distinct inflammatory hair follicle response that includes collapse of immune privilege.
     Br J Dermatol. 2024;191:791-804.
     PubMed     Abstract available
     
     
     
278. BETTUZZI T, Welfringer-Morin A, Ingen-Housz-Oro S, Bataille P, et al
     Comparison of incidence, causes and prognosis of adult and paediatric epidermal necrolysis: a French population-based study.
     Br J Dermatol. 2024;191:698-705.
     PubMed     Abstract available
     
     
     
279. XIONG Y, Xia Y, Zhang X, Jiang B, et al
     Joint exposure to multiple air pollutants, genetic risk, and incident psoriasis: a large-scale prospective cohort study.
     Br J Dermatol. 2024 Oct 12:ljae391. doi: 10.1093.
     PubMed     Abstract available
     
     
     
280. KUMARI R, Apfelbacher CJ, Nelson-Piercy C, Flohr C, et al
     The management of atopic dermatitis in women of childbearing age: confused terminology, lack of evidence and resulting clinical inertia.
     Br J Dermatol. 2024 Oct 12:ljae398. doi: 10.1093.
     PubMed    
     
     
     
281. LAI C, Fuggle NR, Matin RN, Tanaka RJ, et al
     Artificial Intelligence and Machine Learning in Dermatological Research and Healthcare: British Society for Investigative Dermatology Skin Club Report - Southampton April 2024.
     Br J Dermatol. 2024 Oct 12:ljae395. doi: 10.1093.
     PubMed    
     
     
     
282. VAN DER WEYDEN L, Del Castillo Velasco-Herrera M, Cheema S, Wong K, et al
     Comprehensive mutational profiling identifies new driver events in cutaneous leiomyosarcoma.
     Br J Dermatol. 2024 Oct 11:ljae386. doi: 10.1093.
     PubMed     Abstract available
     
     
     
283. 
     Correction to: Single-cell RNA sequencing comparison of CD4+, CD8+ and T-cell receptor gammadelta+ cutaneous T-cell lymphomas reveals subset-specific molecular phenotypes.
     Br J Dermatol. 2024 Oct 11:ljae374. doi: 10.1093.
     PubMed    
     
     
     
284. EJEZIE CL, Ayieko S, Anunobi P, Oladoyin J, et al
     Skin Bleaching: A Socio-ecological Perspective.
     Br J Dermatol. 2024 Oct 9:ljae368. doi: 10.1093.
     PubMed    
     
     
     
285. BLAUVELT A, Reckleff J, Zhao Y, Clark M, et al
     Content Evaluation of Pruritus, Skin Pain, and Sleep Disturbance Patient-Reported Outcome Measures in Adolescents and Adults With Moderate-to-Severe Atopic Dermatitis: Qualitative Interviews.
     Br J Dermatol. 2024 Oct 4:ljae346. doi: 10.1093.
     PubMed     Abstract available
     
     
     
286. KAMMINGA NC, Kievits JE, Plaisier PW, Burgers JS, et al
     Do Large Language Model Chatbots perform better than established patient information resources in answering patient questions? A comparative study on melanoma.
     Br J Dermatol. 2024 Oct 4:ljae377. doi: 10.1093.
     PubMed     Abstract available
     
     
     
287. ROMANI J, Roses C, Brillet F, Fernandez-Vela J, et al
     Microbiome characterization of skin biopsies in Spanish patients with hidradenitis suppurativa shows a decrease in D1 and H1 lineages of Cutibacterium acnes.
     Br J Dermatol. 2024 Oct 1:ljae371. doi: 10.1093.
     PubMed    
     
     
     
288. PANDEYA N, Olsen CM, Neale RE, Whiteman DC, et al
     Melanoma as a detection-dependent cancer: proxy measures of screening and surveillance associated with 3-year incidence of detection procedures for skin cancer in a national prospective study.
     Br J Dermatol. 2024 Oct 1:ljae372. doi: 10.1093.
     PubMed     Abstract available
     
     
     September 2024
289. LAI CC, Shao SC, Tsai ET, Chi CC, et al
     Efficacy and safety of biologics and small molecule inhibitors in treating genital psoriasis: A systematic review of randomised controlled trials.
     Br J Dermatol. 2024 Sep 30:ljae370. doi: 10.1093.
     PubMed    
     
     
     
290. SOUTH AP
     Stopping a runaway train: targeting fibrosis in recessive dystrophic epidermolysis bullosa.
     Br J Dermatol. 2024;191:482-483.
     PubMed    
     
     
     
291. CHEN ML, Kim J, Naik HB, Aleshin MA, et al
     Analysing common topics of secure patient messages in hidradenitis suppurativa: a text-embedding and natural language-processing approach.
     Br J Dermatol. 2024;191:633-635.
     PubMed    
     
     
     
292. CARRASCOSA JM, Munera-Campos M
     Prurigo nodularis: the difference between knowing the path and walking the path.
     Br J Dermatol. 2024;191:480-481.
     PubMed    
     
     
     
293. KIM J, Kim JH
     Clinical relevance of circulating autoantigen-specific T-follicular regulatory cells in pemphigus vulgaris.
     Br J Dermatol. 2024;191:485-486.
     PubMed    
     
     
     
294. BERTOLD C, Delaunay P, Cathelineau AC, Chassang M, et al
     Efficacy of hypnotherapy in chronic idiopathic pruritus: a single-arm prospective pilot study.
     Br J Dermatol. 2024;191:644-645.
     PubMed    
     
     
     
295. AMBER KT, Feldman RJ
     The safety of topical vs. oral steroids in bullous pemphigoid: considerations for retrospective analyses.
     Br J Dermatol. 2024;191:479-480.
     PubMed    
     
     
     
296. HEBERT V, Novarino J, Maho-Vaillant M, Perals C, et al
     The emergence of circulating activated autoreactive desmoglein 3-specific follicular regulatory T cells is associated with long-term efficacy of rituximab in patients with pemphigus vulgaris.
     Br J Dermatol. 2024;191:605-615.
     PubMed     Abstract available
     
     
     
297. BAHLOUL D, Hudson R, Balogh O, Mathias E, et al
     Prevalence, incidence and treatment patterns of prurigo nodularis in England: a retrospective database analysis.
     Br J Dermatol. 2024;191:548-555.
     PubMed     Abstract available
     
     
     
298. BESSIS D, Poujade L, Cossee M, Boursier G, et al
     Mosaic EGFR exon 20 in-frame insertion pathogenic variants are associated with papular epidermal naevus with 'skyline' basal cell layer (PENS).
     Br J Dermatol. 2024;191:641-644.
     PubMed    
     
     
     
299. HUBENTHAL M, Dai C, Brown SJ, Heinrich L, et al
     Mapping SCORing of Atopic Dermatitis (SCORAD) and objective SCORAD to the Eczema Area and Severity Index to facilitate large-scale meta-analyses of molecular data.
     Br J Dermatol. 2024;191:637-639.
     PubMed    
     
     
     
300. PRIMERANO A, De Domenico E, Cianfarani F, De Luca N, et al
     Histone deacetylase inhibition mitigates fibrosis-driven disease progression in recessive dystrophic epidermolysis bullosa.
     Br J Dermatol. 2024;191:568-579.
     PubMed     Abstract available
     
     
     
301. JOHNS JR, Vyas J, Ali FM, Ingram JR, et al
     The Dermatology Life Quality Index as the primary outcome in randomized clinical trials: a systematic review.
     Br J Dermatol. 2024;191:497-507.
     PubMed     Abstract available
     
     
     
302. GARATE D, Thang CJ, Schmidt M, Ravanassa S, et al
     Granuloma annulare and the risk of autoimmune conditions: a multicentre retrospective cohort analysis.
     Br J Dermatol. 2024;191:626-627.
     PubMed    
     
     
     
303. KRIDIN K, Bieber K, Vorobyev A, Moderegger EL, et al
     Risk of death, major adverse cardiac events and relapse in patients with bullous pemphigoid treated with systemic or topical corticosteroids.
     Br J Dermatol. 2024;191:539-547.
     PubMed     Abstract available
     
     
     
304. LYONS D, Louly Nathan A, Pender E, Murray G, et al
     Semaglutide for weight loss in people with obesity as an adjunctive treatment for hidradenitis suppurativa: its impact on disease control and quality of life.
     Br J Dermatol. 2024;191:631-633.
     PubMed    
     
     
     
305. LONG A, O'Malley S, Collins S
     The sunbed trend in Ireland.
     Br J Dermatol. 2024;191:630-631.
     PubMed    
     
     
     
306. ALAVI A, Prens EP, Kimball AB, Frew JW, et al
     Proof-of-concept study exploring the effect of spesolimab in patients with moderate-to-severe hidradenitis suppurativa: a randomized double-blind placebo-controlled clinical trial.
     Br J Dermatol. 2024;191:508-518.
     PubMed     Abstract available
     
     
     
307. CARR DF, Hanson A
     Stevens-Johnson syndrome/toxic epidermal necrolysis: international consensus, advances and opportunities.
     Br J Dermatol. 2024 Sep 16:ljae358. doi: 10.1093.
     PubMed    
     
     
     
308. TENSEN CP, Vermeer MH
     Single cell analyses of cutaneous T-cell lymphoma biopsies.
     Br J Dermatol. 2024 Sep 13:ljae351. doi: 10.1093.
     PubMed    
     
     
     
309. GALENTINE E, Powers CM, McAleer L, Rivera S, et al
     Hidden hurts: life with lichen sclerosus - a patient perspective.
     Br J Dermatol. 2024 Sep 12:ljae357. doi: 10.1093.
     PubMed    
     
     
     
310. STEVENS HP, Pampena R, Farnetani F, Pellicani G, et al
     The use of Reflectance Confocal Microscopy to diagnose Basal Cell Carcinoma in the United Kingdom: A Prospective Observational Trial at a Single Centre.
     Br J Dermatol. 2024 Sep 11:ljae356. doi: 10.1093.
     PubMed     Abstract available
     
     
     
311. STEVENS HP, Pellacani G, Angus C, El-Jabbour JN, et al
     The use of Reflectance Confocal Microscopy to diagnose Malignant Melanoma and Lentigo Maligna in the United Kingdom: A Prospective Observational Trial at a Single Centre.
     Br J Dermatol. 2024 Sep 10:ljae354. doi: 10.1093.
     PubMed     Abstract available
     
     
     
312. HAAG C, Alexis A, Aoki V, Bissonnette R, et al
     A Practical Guide to Using Oral JAK Inhibitors for Atopic Dermatitis from the International Eczema Council.
     Br J Dermatol. 2024 Sep 10:ljae342. doi: 10.1093.
     PubMed     Abstract available
     
     
     
313. MAHUMUD RA
     The emerging burden of melanoma overdiagnosis in Australia: Who bears the cost-patients or the healthcare system?
     Br J Dermatol. 2024 Sep 9:ljae339. doi: 10.1093.
     PubMed    
     
     
     
314. POSADA V, Toland AE
     Role of albinism and pigment-related genes in amelanotic melanoma formation.
     Br J Dermatol. 2024 Sep 9:ljae353. doi: 10.1093.
     PubMed    
     
     
     
315. SIMPSON C, Leducq S, Venables Z, Yiu ZZN, et al
     The association between prescribed oral anti-diabetic medication for type 2 diabetes mellitus and skin cancer risk: a systematic review and meta-analysis.
     Br J Dermatol. 2024 Sep 6:ljae341. doi: 10.1093.
     PubMed    
     
     
     
316. ARDERN-JONES MR, Brown SJ, Flohr C, Hossain P, et al
     An expert consensus on managing dupilumab-related ocular surface disorders in people with atopic dermatitis 2024.
     Br J Dermatol. 2024 Sep 5:ljae344. doi: 10.1093.
     PubMed     Abstract available
     
     
     
317. GELLER AC, Stratigos AJ
     Exploring sex and site- specific differences in melanoma.
     Br J Dermatol. 2024 Sep 4:ljae345. doi: 10.1093.
     PubMed    
     
     
     August 2024
318. YAMAZAKI E, Fujimura T, Takahashi-Watanabe M, Tada S, et al
     Decreased serum levels of IL-4 correlate with the efficacy of the PAI-1 inhibitor TM5614 in patients with malignant melanoma refractory to anti-PD-1 antibodies: post hoc study of TM5614-MM trial.
     Br J Dermatol. 2024 Aug 31:ljae343. doi: 10.1093.
     PubMed    
     
     
     
319. WEI L, Fitzgerald ME, Yan L, Murakami M, et al
     Photodynamic therapy reduces the burden of small ultraviolet-induced epidermal clones in human and mouse skin.
     Br J Dermatol. 2024 Aug 27:ljae314. doi: 10.1093.
     PubMed    
     
     
     
320. AHMED A, Mohandas P, Taylor R, Assalman I, et al
     'Psycholag': a new term to describe the delay between physical and psychological improvement in patients with skin disease.
     Br J Dermatol. 2024 Aug 22:ljae333. doi: 10.1093.
     PubMed    
     
     
     
321. GIPPLE MO, Dhami RK, Latour E, Keller JJ, et al
     Morgellons disease shows a lower quality of life than psoriasis, atopic dermatitis, and prurigo nodularis.
     Br J Dermatol. 2024 Aug 21:ljae335. doi: 10.1093.
     PubMed    
     
     
     
322. STURM RA, Smit DJ, Duffy DL, McLean C, et al
     Uncovering molecular mechanisms for amelanotic/hypopigmented primary cutaneous melanoma.
     Br J Dermatol. 2024 Aug 21:ljae336. doi: 10.1093.
     PubMed     Abstract available
     
     
     
323. SERVATTALAB SE, Lee M, Hlobik M, Song H, et al
     Examining racial and ethnic disparities in diagnosis and access to care in infantile atopic dermatitis in the United States: a retrospective cohort study.
     Br J Dermatol. 2024 Aug 20:ljae322. doi: 10.1093.
     PubMed     Abstract available
     
     
     
324. O'REILLY P, Walsh S, Bunker CB, Ryan S, et al
     The quality-of-life impact of Stevens-Johnson syndrome (SJS) and toxic epidermal necrolysis (TEN) on patients' lives: An interpretative descriptive qualitative study.
     Br J Dermatol. 2024 Aug 20:ljae334. doi: 10.1093.
     PubMed     Abstract available
     
     
     
325. KPENOU FC, Paul C, Seneschal J, Andreu N, et al
     The Atopic Dermatitis Patient Journey: Insights from a Qualitative Study.
     Br J Dermatol. 2024 Aug 18:ljae329. doi: 10.1093.
     PubMed    
     
     
     
326. CHIESA FUXENCH ZC, Mitra N, Grice E, Hoffstad O, et al
     Is seborrhoeic dermatitis of infancy and childhood related to maternal history of seborrhoeic dermatitis? A large population-based cohort study from the UK.
     Br J Dermatol. 2024 Aug 18:ljae331. doi: 10.1093.
     PubMed     Abstract available
     
     
     
327. KORTE EWH, Pasmooij AMG, Bolling MC, Hickey S, et al
     Towards a roadmap for COSEB: the next steps in harmonization of outcomes for epidermolysis bullosa.
     Br J Dermatol. 2024;191:463-465.
     PubMed    
     
     
     
328. OH BH, Kim KH
     Applying a novel optical technique for residual cancer detection with accuracy evaluation: a cornerstone for field implementation.
     Br J Dermatol. 2024;191:322-323.
     PubMed    
     
     
     
329. EHIZOGIE E, Maghari I, Lo S, Albrecht J, et al
     Hidradenitis suppurativa, systemic inflammatory response syndrome and sepsis: a database study.
     Br J Dermatol. 2024;191:451-453.
     PubMed    
     
     
     
330. CURMAN P, Jebril W, Larsson H, Bachar-Wikstrom E, et al
     Increased risk of depression and anxiety in individuals with Darier disease.
     Br J Dermatol. 2024;191:462-463.
     PubMed    
     
     
     
331. YIU D, Aguilar-Duran S, Edwards C, Chauhan D, et al
     Increased incidence of co-trimoxazole-induced rash in patients on systemic corticosteroid treatment for toxicity associated with immune checkpoint inhibitors.
     Br J Dermatol. 2024;191:465-467.
     PubMed    
     
     
     
332. DALE C, Hewitt RM, Purcell C, Pandya N, et al
     'Feeling like a second-class citizen': exploring the impact, self-management and existing support for adults living with acne and/or post-inflammatory hyperpigmentation and scarring.
     Br J Dermatol. 2024;191:469-470.
     PubMed    
     
     
     
333. HAS C
     MiTES: itch or pain?
     Br J Dermatol. 2024;191:323-324.
     PubMed    
     
     
     
334. RHODES LE
     Vitamin D status in patients with erythropoietic protoporphyria taking the systemic photoprotective agent afamelanotide.
     Br J Dermatol. 2024;191:317-318.
     PubMed    
     
     
     
335. STADLER R
     The interferon story continues: EORTC CLTG study explores pegylated interferon alpha-2a's role in treating mycosis fungoides/Sezary syndrome.
     Br J Dermatol. 2024;191:321-322.
     PubMed    
     
     
     
336. DEKKERS C, de Bruin-Weller M
     The pleiotropic role of interleukin-13 in the pathogenesis of atopic dermatitis.
     Br J Dermatol. 2024;191:316-317.
     PubMed    
     
     
     
337. MAGHARI I, Abiad H, Griffin T, Albrecht J, et al
     Hidradenitis suppurativa (HS), systemic inflammatory response syndrome and sepsis, sepsis caused by HS: an empty systematic review.
     Br J Dermatol. 2024;191:449-450.
     PubMed    
     
     
     
338. KLUIJVER LG, Nekouei Shahraki M, Wagenmakers MAEM, Hanssen BE, et al
     The effects of cholecalciferol and afamelanotide on vitamin D levels in erythropoietic protoporphyria: a multicentre cohort study.
     Br J Dermatol. 2024;191:357-364.
     PubMed     Abstract available
     
     
     
339. MITSUNAGA K, Bagot M, Ram-Wolff C, Guenova E, et al
     Real-world study of pegylated interferon alpha-2a to treat mycosis fungoides/Sezary syndrome using time to next treatment as a measure of clinical benefit: an EORTC CLTG study.
     Br J Dermatol. 2024;191:419-427.
     PubMed     Abstract available
     
     
     
340. COHN E, Palma G, Mastacouris N, Strunk A, et al
     Incidence of anxiety disorder in adults with hidradenitis suppurativa.
     Br J Dermatol. 2024;191:351-356.
     PubMed     Abstract available
     
     
     
341. NOCHAIWONG S, Ruengorn C, Thavorn K, Noppakun K, et al
     Psychometric evaluation of the multidimensional Uraemic Pruritus in Dialysis patients (UP-Dial) scale: comparison of haemodialysis and peritoneal dialysis patients with chronic pruritus.
     Br J Dermatol. 2024;191:375-384.
     PubMed     Abstract available
     
     
     
342. SIBBALD C, Castelo-Soccio L
     Review of global epidemiology data for alopecia areata highlights gaps and a call for action.
     Br J Dermatol. 2024;191:315-316.
     PubMed    
     
     
     
343. JEON JJ, Jung SW, Kim YH, Parisi R, et al
     Global, regional and national epidemiology of alopecia areata: a systematic review and modelling study.
     Br J Dermatol. 2024;191:325-335.
     PubMed     Abstract available
     
     
     
344. BANERJEE A, Ezzedine K, Shore R, Peeva E, et al
     An analysis of inter- and intra-rater Facial Vitiligo Area Scoring Index assessments in adults with active nonsegmental vitiligo.
     Br J Dermatol. 2024;191:453-454.
     PubMed    
     
     
     
345. HAMA N, Aoki S, Chen CB, Hasegawa A, et al
     Recent progress of Stevens-Johnson syndrome/toxic epidermal necrolysis: Diagnosis criteria, pathogenesis and therapy.
     Br J Dermatol. 2024 Aug 14:ljae321. doi: 10.1093.
     PubMed     Abstract available
     
     
     
346. CHENNAREDDY S, Rindler K, Ruggiero JR, Alkon N, et al
     Single-cell RNA sequencing comparison of CD4+, CD8+ and TCR-gammadelta+ cutaneous T-cell lymphomas reveals subset-specific molecular phenotypes.
     Br J Dermatol. 2024 Aug 12:ljae313. doi: 10.1093.
     PubMed     Abstract available
     
     
     
347. KIM SR, Choi YG, Jo SJ
     Duration of smoking cessation for the prevention of psoriasis vulgaris and palmoplantar pustulosis.
     Br J Dermatol. 2024 Aug 6:ljae317. doi: 10.1093.
     PubMed    
     
     
     
348. FANG Y, Qi J, Jiang Y, Lin Z, et al
     Fish oil supplementation protects skin from yellowness induced by fine particulate matter through anti-inflammatory mechanism: a randomized, double-blind, placebo-controlled clinical trial.
     Br J Dermatol. 2024 Aug 5:ljae311. doi: 10.1093.
     PubMed    
     
     
     July 2024
349. RAYMUNDO C, Cella D, Wagner L, Hippe DS, et al
     Development and psychometric properties of the Functional Assessment of Cancer Therapy-Cutaneous T-Cell Lymphoma (FACT-CTCL).
     Br J Dermatol. 2024 Jul 30:ljae308. doi: 10.1093.
     PubMed     Abstract available
     
     
     
350. WILLEMZE R
     Primary cutaneous acral CD8+ T-cell lymphoproliferative disorder: a benign or malignant process?
     Br J Dermatol. 2024 Jul 26:ljae303. doi: 10.1093.
     PubMed    
     
     
     
351. DE BRITO M, O'Toole EA
     Exploring the role of cytokeratin-17 in skin tumourigenesis and HPV persistence.
     Br J Dermatol. 2024 Jul 25:ljae294. doi: 10.1093.
     PubMed    
     
     
     
352. ALEXANDER H, Malek R, Prieto-Merino D, Gribaleva E, et al
     A prospective observational cohort study comparing the treatment effectiveness and safety of ciclosporin, dupilumab and methotrexate in adult and paediatric patients with atopic dermatitis: results from the UK-Irish A-STAR register.
     Br J Dermatol. 2024 Jul 24:ljae287. doi: 10.1093.
     PubMed     Abstract available
     
     
     
353. VAN DOORN R
     Supplemental vitamin D on trial: no evidence of benefit as an adjuvant treatment for melanoma.
     Br J Dermatol. 2024 Jul 23:ljae302. doi: 10.1093.
     PubMed    
     
     
     
354. LINDSAY D, Bell KJL, Olsen CM, Whiteman DC, et al
     Estimating the magnitude and healthcare costs of melanoma in situ and thin invasive melanoma overdiagnosis in Australia.
     Br J Dermatol. 2024 Jul 19:ljae296. doi: 10.1093.
     PubMed     Abstract available
     
     
     
355. OLSEN CM, Pandeya N, Neale RE, Law MH, et al
     Phenotypic and genotypic risk factors for invasive melanoma by sex and body site.
     Br J Dermatol. 2024 Jul 19:ljae297. doi: 10.1093.
     PubMed     Abstract available
     
     
     
356. HARRISON SR, Campbell F, Bennett H, De Marco G, et al
     High prevalence of undiagnosed and undertreated psoriasis in a UK urban population: results from the observational COPPACA study.
     Br J Dermatol. 2024 Jul 19:ljae292. doi: 10.1093.
     PubMed    
     
     
     
357. RENTROIA-PACHECO B, Shain AH
     Cutaneous squamous cell carcinoma progression: what does a meta-analysis of transcriptomic studies tell us?
     Br J Dermatol. 2024 Jul 17:ljae293. doi: 10.1093.
     PubMed    
     
     
     
358. MACAULAY ARK, Yang J, Price MA, Forster CL, et al
     Chondroitin sulfate proteoglycan 4 (CSPG4) increases invasion of recessive dystrophic epidermolysis bullosa-associated cutaneous squamous cell carcinoma by modifying TGFbeta signaling.
     Br J Dermatol. 2024 Jul 17:ljae295. doi: 10.1093.
     PubMed     Abstract available
     
     
     
359. 
     Correction to: Prevalence, incidence, mortality and healthcare resource use for generalized pustular psoriasis, palmoplantar pustulosis and plaque psoriasis in England: a population-based cohort study.
     Br J Dermatol. 2024 Jul 17:ljae285. doi: 10.1093.
     PubMed    
     
     
     
360. 
     New British Skin Foundation/Skin Health Alliance Psychodermatology Research Award now available.
     Br J Dermatol. 2024;191:309.
     PubMed    
     
     
     
361. BATTISTELLA M
     Paediatric lymphomatoid papulosis: a benign clonal T-cell disorder that is a harbinger of haematological malignancy.
     Br J Dermatol. 2024;191:158-159.
     PubMed    
     
     
     
362. DOOLAN BJ, Thomas BR
     Bursting the bubble on diagnostics: artificial intelligence in autoimmune bullous disease.
     Br J Dermatol. 2024;191:160-161.
     PubMed    
     
     
     
363. ANDRADE LF, Haq Z, Abdi P, Diaz MJ, et al
     Impact of pruritus on patient fatigue: a cross-sectional study.
     Br J Dermatol. 2024;191:292-293.
     PubMed    
     
     
     
364. REICH A
     Nemolizumab: a new key player in the treatment of prurigo nodularis.
     Br J Dermatol. 2024;191:154-155.
     PubMed    
     
     
     
365. THEIN D, Maul JT, Schmid-Grendelmeier P, Thyssen JP, et al
     Prevalence of ichthyoses in Denmark: a nationwide registry-based study.
     Br J Dermatol. 2024;191:305-306.
     PubMed    
     
     
     
366. SAMUELOV L
     Dystrophic epidermolysis bullosa: from disease biology to biologic therapy.
     Br J Dermatol. 2024;191:159-160.
     PubMed    
     
     
     
367. GAMBICHLER T, Razeghpour F, Sorescu E, Stucker M, et al
     High intratumoral 5-hydroxymethylcytosine levels protect against disease relapse in patients with atypical fibroxanthoma and pleomorphic dermal sarcoma.
     Br J Dermatol. 2024;191:295-296.
     PubMed    
     
     
     
368. GUPTA V, Taneja N, Sati HC, Sreenivas V, et al
     'Substantial clinical benefit' and 'substantial clinical worsening' cutoff of Vitiligo Impact Scale (VIS)-22 change scores.
     Br J Dermatol. 2024;191:307-308.
     PubMed    
     
     
     
369. GRATTAN CEH, Kocaturk E
     How relevant are eosinophils to chronic spontaneous urticaria? No evidence of clinical benefit from eosinophil depletion with benralizumab.
     Br J Dermatol. 2024;191:153-154.
     PubMed    
     
     
     
370. SARKOVICS K, Kolodney JA, Kolodney MS
     Programmed death receptor-1 and programmed death ligand-1 checkpoint inhibition-associated bullous pemphigoid: a propensity-matched retrospective cohort study.
     Br J Dermatol. 2024;191:299-300.
     PubMed    
     
     
     
371. YOKOZEKI H, Murota H, Matsumura T, Komazaki H, et al
     Efficacy and safety of nemolizumab and topical corticosteroids for prurigo nodularis: results from a randomized double-blind placebo-controlled phase II/III clinical study in patients aged >/= 13 years.
     Br J Dermatol. 2024;191:200-208.
     PubMed     Abstract available
     
     
     
372. BRAZZELLI V, Michelerio A
     Use of a large patient database to analyse disease burden and treatment patterns among patients with vitiligo.
     Br J Dermatol. 2024;191:156-157.
     PubMed    
     
     
     
373. MCCARTHY RL, Schwartz J, Oldham J, Bodemer C, et al
     A cross-sectional study of erythromelalgia in patients with pachyonychia congenita.
     Br J Dermatol. 2024;191:300-302.
     PubMed    
     
     
     
374. CAPURRO N, Pastore VP, Touijer L, Odone F, et al
     A deep learning approach to direct immunofluorescence pattern recognition in autoimmune bullous diseases.
     Br J Dermatol. 2024;191:261-266.
     PubMed     Abstract available
     
     
     
375. ELEFTHERIADOU V, Delattre C, Chetty-Mhlanga S, Lee C, et al
     Burden of disease and treatment patterns in patients with vitiligo: findings from a national longitudinal retrospective study in the UK.
     Br J Dermatol. 2024;191:216-224.
     PubMed     Abstract available
     
     
     
376. LAIMER M
     Nonsense variant readthrough therapy for epidermolysis bullosa.
     Br J Dermatol. 2024;191:161-162.
     PubMed    
     
     
     
377. CAMPBELL F, Laws P
     Managing risk of liver fibrosis in patients with psoriasis being considered for methotrexate.
     Br J Dermatol. 2024;191:163.
     PubMed    
     
     
     
378. ALTRICHTER S, Gimenez-Arnau AM, Bernstein JA, Metz M, et al
     Benralizumab does not elicit therapeutic effect in patients with chronic spontaneous urticaria: results from the phase IIb multinational randomized double-blind placebo-controlled ARROYO trial.
     Br J Dermatol. 2024;191:187-199.
     PubMed     Abstract available
     
     
     
379. WOODLEY DT, Hao M, Kwong A, Levian B, et al
     Intravenous gentamicin therapy induces functional type VII collagen in patients with recessive dystrophic epidermolysis bullosa: an open-label clinical trial.
     Br J Dermatol. 2024;191:267-274.
     PubMed     Abstract available
     
     
     
380. HOWELLS L
     Patient-Reported Impact of Dermatological Diseases (PRIDD) is a new patient-reported outcome measure for dermatology: why is it needed?
     Br J Dermatol. 2024;191:e4.
     PubMed    
     
     
     
381. XU Y, Guo L, Wu S, Zhang T, et al
     Causal effect of elevated body mass index on hidradenitis suppurativa: a two-sample Mendelian randomization study.
     Br J Dermatol. 2024;191:290-292.
     PubMed    
     
     
     
382. HUANG Y, Pu W, Wang L, Ma Q, et al
     ACKR1+ Endothelial Cells Mediate Leukocyte Infiltration and Synergize with SFRP2/ASPN+ Fibroblasts to Promote Skin Fibrosis in Systemic Sclerosis.
     Br J Dermatol. 2024 Jul 15:ljae286. doi: 10.1093.
     PubMed     Abstract available
     
     
     
383. BRUCE G, Rosala-Hallas A, Jones AP, Turner C, et al
     The effects of ciclosporin and methotrexate on kidney function in the treatment of severe atopic dermatitis in children - results from the TREAT trial.
     Br J Dermatol. 2024 Jul 15:ljae276. doi: 10.1093.
     PubMed    
     
     
     
384. WANG H, Wu Y, Bassetti JA, Wang Z, et al
     A gain-of-function variant in SREBF1 causes generalized skin hyperpigmentation with congenital cataracts.
     Br J Dermatol. 2024 Jul 15:ljae291. doi: 10.1093.
     PubMed     Abstract available
     
     
     
385. LI A, Musters AH, Hyseni A, Gerbens LAA, et al
     Dupilumab-associated (hyper)eosinophilia in patients with atopic dermatitis: a single-center cohort study of the TREAT NL (TREatment of ATopic eczema, the Netherlands) registry.
     Br J Dermatol. 2024 Jul 15:ljae289. doi: 10.1093.
     PubMed    
     
     
     
386. LALLAS K, Spyridonos P, Kittler H, Tschandl P, et al
     Prediction of melanoma metastasis using dermatoscopy deep features. An international multicenter cohort study.
     Br J Dermatol. 2024 Jul 12:ljae281. doi: 10.1093.
     PubMed    
     
     
     
387. DAVITI M, Papadimitriou I, Cinotti E, Lallas A, et al
     Atypical melanocytes of an Atypical Spitz Tumor observed with Optical Super-High Magnification Dermoscopy.
     Br J Dermatol. 2024 Jul 2:ljae277. doi: 10.1093.
     PubMed    
     
     
     
388. JIA Q, Cao Q, Peng C, Shui X, et al
     Predictive features for effectiveness of dupilumab in elderly patients with atopic dermatitis: a real-world study.
     Br J Dermatol. 2024 Jul 2:ljae278. doi: 10.1093.
     PubMed    
     
     
     
389. KLEEMANN J, Schilling B
     Multicenter phase II trial of plasminogen activator inhibitor-1 inhibitor (TM5614) plus nivolumab in japanese advanced melanoma patients: Immune resistance remains one of the major efforts in melanoma research.
     Br J Dermatol. 2024 Jul 2:ljae279. doi: 10.1093.
     PubMed    
     
     
     June 2024
390. SCHIELEIN L, Ziehfreund S, Biedermann T, Zink A, et al
     "When you do not feel comfortable in your skin, you cannot get out of it" - A Qualitative Interview Study exploring Psychosocial Impact and Coping Strategies among Patients with Prurigo Nodularis.
     Br J Dermatol. 2024 Jun 28:ljae274. doi: 10.1093.
     PubMed    
     
     
     
391. WOBSE M, Appenzeller S, Roth S, Siedel C, et al
     Oncogenic alterations in KIR3DL1 in cutaneous acral CD8+ lymphoproliferative disorder.
     Br J Dermatol. 2024 Jun 27:ljae256. doi: 10.1093.
     PubMed     Abstract available
     
     
     
392. HAGENSTROM K, Klinger T, Muller K, Willers C, et al
     Utilization and related harms of systemic glucocorticosteroids for atopic dermatitis: claims data analysis.
     Br J Dermatol. 2024 Jun 27:ljae250. doi: 10.1093.
     PubMed     Abstract available
     
     
     
393. VON KOBYLETZKI LB, Svensson A
     Generalised pustular psoriasis, palmoplantar pustulosis, and plaque psoriasis have different survival rates and health care needs.
     Br J Dermatol. 2024 Jun 25:ljae271. doi: 10.1093.
     PubMed    
     
     
     
394. ESPOSITO M, Yerly L, Shukla P, Hermes V, et al
     COL10A1 expression distinguishes a subset of cancer-associated fibroblasts present in the stroma of high-risk basal cell carcinoma.
     Br J Dermatol. 2024 Jun 25:ljae258. doi: 10.1093.
     PubMed     Abstract available
     
     
     
395. DE SMEDT J, Van Kelst S, Janssen L, Marasigan V, et al
     High dose vitamin D supplementation does not improve outcome in a cutaneous melanoma population: results of a randomized double-blind, placebo-controlled study (ViDMe trial).
     Br J Dermatol. 2024 Jun 24:ljae257. doi: 10.1093.
     PubMed     Abstract available
     
     
     
396. 
     Long-term response to treatment with guselkumab in people with moderate-to-severe psoriasis.
     Br J Dermatol. 2024;191:e3.
     PubMed    
     
     
     
397. TZOUMPA S, Ingen-Housz-Oro S, de Masson A, Pham-Ledard A, et al
     Evolution of patients with Sezary syndrome after mogamulizumab discontinuation for any cause except progression: a multicentre retrospective study (Moga-stop Study).
     Br J Dermatol. 2024;191:143-144.
     PubMed    
     
     
     
398. XIE W, Kong X, Liu W, Liang G, et al
     Antifungal-resistant Trichophyton indotineae: transmission warrants priority attention and international collaboration.
     Br J Dermatol. 2024;191:146-147.
     PubMed    
     
     
     
399. HORISSIAN M, Samaan C, Cohrs A, Kirby J, et al
     Trends in antibiotic prescriptions for hidradenitis suppurativa from 2015 to 2021.
     Br J Dermatol. 2024;191:142-143.
     PubMed    
     
     
     
400. ABDOLRASOULI A, Hay RJ
     Antifungal-resistant Trichophyton indotineae: transmission is occurring outside previously identified endemic areas - are we prepared?
     Br J Dermatol. 2024;191:145-146.
     PubMed    
     
     
     
401. DANBY SG
     Debunking the myth that all emollients are equal opens the door for future atopic dermatitis prevention studies.
     Br J Dermatol. 2024;191:6-7.
     PubMed    
     
     
     
402. TULL TJ, Benton EC, Semkova K, Watson NA, et al
     Combined rituximab and belimumab to treat recalcitrant epidermolysis bullosa aquisita associated with systemic lupus erythematosus.
     Br J Dermatol. 2024;191:138-140.
     PubMed    
     
     
     
403. GOLETZ S, Probst C, Komorowski L, Radzimski C, et al
     Sensitive and specific assay for the serological diagnosis of anti-p200 pemphigoid based on the recombinant laminin beta4 subunit.
     Br J Dermatol. 2024;191:140-141.
     PubMed    
     
     
     
404. LIU Y, Liu J, Chen Y, Mo R, et al
     Potential digenic inheritance of SERPINB7 and SERPINA12 variants in Chinese patients with Nagashima-type palmoplantar keratosis.
     Br J Dermatol. 2024;191:136-138.
     PubMed    
     
     
     
405. LIANG L, Peng S, Huang S, Wang H, et al
     Progressive hyperpigmentation and lentigines due to KIT variants improving with imatinib.
     Br J Dermatol. 2024;191:148-149.
     PubMed    
     
     
     
406. KEARNEY N, Kirby B
     Prior exposure to fumaric acid esters does not impact on subsequent treatment response to guselkumab.
     Br J Dermatol. 2024;191:5-6.
     PubMed    
     
     
     
407. SALAMON G, Strobl S, Field-Werners U, Diem A, et al
     Psychometric Properties of the Instrument for Scoring Clinical Outcomes of Research for Epidermolysis Bullosa patient score (iscorEB-p): a patient-reported outcome measure.
     Br J Dermatol. 2024;191:75-81.
     PubMed     Abstract available
     
     
     
408. THACI D, Pinter A, Sebastian M, Termeer C, et al
     Guselkumab demonstrates long-term efficacy and maintenance of treatment response postwithdrawal in systemic treatment-naive patients and nonresponders to fumaric acid esters: results from parts II and III of a randomized active-comparator-controlled p
     Br J Dermatol. 2024;191:36-48.
     PubMed     Abstract available
     
     
     
409. HASCHE D, Hufbauer M, Braspenning-Wesch I, Stephan S, et al
     Cytokeratin-17 expression is commonly observed in keratinocytic skin tumours and controls tissue homeostasis impacting HPV protein expression.
     Br J Dermatol. 2024 Jun 15:ljae255. doi: 10.1093.
     PubMed     Abstract available
     
     
     
410. MCMAHON M, Deacon DC
     Spatial sequencing reveals transcriptional variation between amelanotic and pigmented acral melanoma.
     Br J Dermatol. 2024 Jun 15:ljae253. doi: 10.1093.
     PubMed    
     
     
     
411. FISCHER G
     The impact of vulval lichen sclerosus in young people: a call for better awareness, individualised maintenance plans and revised guidelines.
     Br J Dermatol. 2024 Jun 15:ljae254. doi: 10.1093.
     PubMed    
     
     
     
412. BENCOMO T, Lee CS
     Gene expression landscape of cutaneous squamous cell carcinoma progression.
     Br J Dermatol. 2024 Jun 13:ljae249. doi: 10.1093.
     PubMed     Abstract available
     
     
     
413. BARBAROT S, Aubert H, Vibet MA, Leray M, et al
     Effectiveness of a nurse-led one-to-one education programme in addition to standard care in children with atopic dermatitis: a multicentre randomized control trial.
     Br J Dermatol. 2024 Jun 12:ljae111. doi: 10.1093.
     PubMed     Abstract available
     
     
     
414. FISCHER J
     Confetti Cure: Reversing the Genetic Kaleidoscope of Ichthyosis.
     Br J Dermatol. 2024 Jun 11:ljae248. doi: 10.1093.
     PubMed    
     
     
     
415. MITRA R, Fitzsimmons H, Hale T, Tan ST, et al
     Recent Advances in Understanding the Molecular Basis of Infantile Haemangioma Development.
     Br J Dermatol. 2024 Jun 7:ljae241. doi: 10.1093.
     PubMed     Abstract available
     
     
     
416. VENABLES ZC, Wakkee M
     Basal cell carcinoma incidence trends - can we stop the surge?
     Br J Dermatol. 2024 Jun 5:ljae239. doi: 10.1093.
     PubMed    
     
     
     
417. LOUVEAU B, Nakouri I, Jouenne F, Baroudjian B, et al
     Genomic profiling of a skin adnexal carcinomas cohort using a comprehensive high throughput sequencing approach.
     Br J Dermatol. 2024 Jun 5:ljae233. doi: 10.1093.
     PubMed    
     
     
     
418. GUTTMAN-YASSKY E, Croft M, Geng B, Rynkiewicz N, et al
     The role of OX40L/OX40 axis signalling in atopic dermatitis.
     Br J Dermatol. 2024 Jun 5:ljae230. doi: 10.1093.
     PubMed     Abstract available
     
     
     
419. FUJIMURA T, Yoshino K, Kato H, Fukushima S, et al
     Phase II, multicenter study of plasminogen activator inhibitor-1 inhibitor (TM5614) plus nivolumab for treating anti-PD-1 antibody-refractory malignant melanoma: TM5614-MM trial.
     Br J Dermatol. 2024 Jun 4:ljae231. doi: 10.1093.
     PubMed     Abstract available
     
     
     May 2024
420. KISS O, Bahri R, Watson REB, Chike C, et al
     The impact of irritant challenge on the skin barrier and myeloid resident immune cells in post-menopausal women is modulated by hormone replacement therapy.
     Br J Dermatol. 2024 May 31:ljae226. doi: 10.1093.
     PubMed     Abstract available
     
     
     
421. CHOI ME, Choi EJ, Lee JH, Won CH, et al
     Spatial transcriptome analysis of amelanotic acral melanoma reveals distant molecular determinants compared to pigmented acral melanoma.
     Br J Dermatol. 2024 May 30:ljae224. doi: 10.1093.
     PubMed     Abstract available
     
     
     
422. SHEN CH, Yang YS, Lee IT, Chiang MH, et al
     Sodium-glucose cotransporter protein-2 inhibitors for diabetes and the reduced risk of inflammatory skin diseases.
     Br J Dermatol. 2024 May 29:ljae229. doi: 10.1093.
     PubMed    
     
     
     
423. BARBIERI A, Orloff J, Gulati N, Brown RM, et al
     Living in my own skin: dermatological concerns and gender-affirming care as a trans person with neurofibromatosis type 1.
     Br J Dermatol. 2024 May 27:ljae170. doi: 10.1093.
     PubMed    
     
     
     
424. VAHER H
     Expanding the knowledge about the TNF-alpha induced GSDME-mediated pyroptosis in psoriasis.
     Br J Dermatol. 2024 May 23:ljae223. doi: 10.1093.
     PubMed    
     
     
     
425. LUO L, Cheng H, Liu Z, Olszewski P, et al
     Single-cell transcriptomic analysis identifies infiltrating plasmacytoid dendritic cells in psoriasis epidermis.
     Br J Dermatol. 2024 May 22:ljae210. doi: 10.1093.
     PubMed    
     
     
     
426. 
     Correction to: Loss-of-function variants in GLMN are associated with generalized skin hyperpigmentation with or without glomuvenous malformation.
     Br J Dermatol. 2024 May 22:ljae212. doi: 10.1093.
     PubMed    
     
     
     
427. FRYSZ M, Patel S, Li MOY, Griffiths CEM, et al
     Prevalence, incidence, mortality, and healthcare resource use for generalised pustular psoriasis, palmoplantar pustulosis, and plaque psoriasis in England: a population-based cohort study.
     Br J Dermatol. 2024 May 22:ljae217. doi: 10.1093.
     PubMed     Abstract available
     
     
     
428. HANRAHAN GB, Tsibris HC
     Mutational Landscape and Tumor Mutational Burden in Adult Patients with Malignant Melanoma Arising From Congenital Nevi.
     Br J Dermatol. 2024 May 21:ljae214. doi: 10.1093.
     PubMed    
     
     
     
429. MORREL B, Kampherbeek JHJ, Ten Kate-Booij MJ, van der Avoort IAM, et al
     Growing up with juvenile vulvar lichen sclerosus, the experiences and care needs of adult women with lichen sclerosus since childhood: a qualitative exploration.
     Br J Dermatol. 2024 May 21:ljae203. doi: 10.1093.
     PubMed     Abstract available
     
     
     
430. 
     Correction to: Breastfeeding decreases the risk of developing psoriasis through to early adulthood.
     Br J Dermatol. 2024 May 20:ljae208. doi: 10.1093.
     PubMed    
     
     
     
431. 
     Contact allergies to dental material.
     Br J Dermatol. 2024;190:e66.
     PubMed    
     
     
     
432. 
     Predicting the likelihood of hidradenitis suppurativa disease progression based on identified risk factors.
     Br J Dermatol. 2024;190:e67.
     PubMed    
     
     
     
433. 
     The impact of atopic dermatitis on children and adolescents.
     Br J Dermatol. 2024;190:e65.
     PubMed    
     
     
     
434. 
     Incidence, mortality and survival in people with Merkel cell carcinoma: a systematic review.
     Br J Dermatol. 2024;190:e64.
     PubMed    
     
     
     
435. PAVLENKO D, Akiyama T
     Cryosim-1: a cool solution for acute and chronic itch.
     Br J Dermatol. 2024;190:787.
     PubMed    
     
     
     
436. THANG CJ, Garate D, O'Leary S, Golovko G, et al
     Evaluation of the association between tetracycline-class antibiotic use in patients with acne and idiopathic intracranial hypertension risk: a population-level cohort study.
     Br J Dermatol. 2024;190:921-923.
     PubMed    
     
     
     
437. JAMES M, Nakamura M, Whittaker S, Morris S, et al
     Mycosis fungoides: successful re-treatment with brentuximab vedotin.
     Br J Dermatol. 2024;190:929-930.
     PubMed    
     
     
     
438. ZOUBOULIS CC, Passeron T, Pariser D, Wozniak MB, et al
     Secukinumab in patients with moderate-to-severe hidradenitis suppurativa based on prior biologic exposure: an efficacy and safety analysis from the SUNSHINE and SUNRISE phase III trials.
     Br J Dermatol. 2024;190:836-845.
     PubMed     Abstract available
     
     
     
439. KIM DY
     Mortality landscape of Behcet disease.
     Br J Dermatol. 2024;190:784.
     PubMed    
     
     
     
440. BAHAR F, DeCaprio JA
     Why do we distinguish between virus-positive and virus-negative Merkel cell carcinoma?
     Br J Dermatol. 2024;190:785-786.
     PubMed    
     
     
     
441. LIAO V, Cornman HL, Ma E, Kwatra SG, et al
     Prurigo nodularis: new insights into pathogenesis and novel therapeutics.
     Br J Dermatol. 2024;190:798-810.
     PubMed     Abstract available
     
     
     
442. LEE S, Wei ET, Selescu T, Babes A, et al
     Histamine- and pruritogen-induced itch is inhibited by a TRPM8 agonist: a randomized vehicle-controlled human trial.
     Br J Dermatol. 2024;190:885-894.
     PubMed     Abstract available
     
     
     
443. GORDON ER, Trager MH, Kontos D, Weng C, et al
     Ethical considerations for artificial intelligence in dermatology: a scoping review.
     Br J Dermatol. 2024;190:789-797.
     PubMed     Abstract available
     
     
     
444. CHOI SR, Shin A, Ha YJ, Lee YJ, et al
     All-cause and cause-specific mortality in patients with Behcet disease versus the general population.
     Br J Dermatol. 2024;190:858-866.
     PubMed     Abstract available
     
     
     
445. JOHNSON O
     Living with nodular prurigo.
     Br J Dermatol. 2024;190:915.
     PubMed    
     
     
     
446. GREKOWITZ E, Metz M, Altrichter S, Bauer A, et al
     Targeting histamine receptor 4 in cholinergic urticaria with izuforant (LEO 152020): results from a phase IIa randomized double-blind placebo-controlled multicentre crossover trial.
     Br J Dermatol. 2024;190:825-835.
     PubMed     Abstract available
     
     
     
447. MARONESE CA, Marzano AV
     Identifying candidates for early intervention in hidradenitis suppurativa.
     Br J Dermatol. 2024;190:787-788.
     PubMed    
     
     
     
448. RAGAMIN A, Zhang J, Pasmans SGMA, Schappin R, et al
     The construct validity, responsiveness, reliability and interpretability of the Recap of atopic eczema questionnaire (RECAP) in children.
     Br J Dermatol. 2024;190:867-875.
     PubMed     Abstract available
     
     
     
449. TORRE-CASTRO J, Rodriguez M, Alonso-Alonso R, Mendoza Cembranos MD, et al
     LT and SOX9 expression are associated with gene sets that distinguish Merkel cell polyomavirus (MCPyV)-positive and MCPyV-negative Merkel cell carcinoma.
     Br J Dermatol. 2024;190:876-884.
     PubMed     Abstract available
     
     
     
450. KJAERSGAARD ANDERSEN R, Pedersen O, Eidsmo L, Jemec G, et al
     Initial steps towards developing a predictive algorithm of disease progression for hidradenitis suppurativa (HS): results from a Cox proportional hazard regression analysis on disease progression among a cohort of 335 Danish patients with HS.
     Br J Dermatol. 2024;190:904-914.
     PubMed     Abstract available
     
     
     
451. CHIESA FUXENCH ZC
     The burden of atopic dermatitis across paediatric populations: 'it's not just an itch that rashes'.
     Br J Dermatol. 2024;190:783-784.
     PubMed    
     
     
     
452. MISTRY K, Venables ZC
     A systematic review of Merkel cell carcinoma epidemiology highlights its rising incidence, poor prognosis and data heterogeneity.
     Br J Dermatol. 2024;190:782-783.
     PubMed    
     
     
     
453. MOHSEN ST, Price EL, Chan AW, Hanna TP, et al
     Incidence, mortality and survival of Merkel cell carcinoma: a systematic review of population-based studies.
     Br J Dermatol. 2024;190:811-824.
     PubMed     Abstract available
     
     
     
454. OLSEN CM
     Ecological evidence for melanoma overdiagnosis in Denmark.
     Br J Dermatol. 2024 May 16:ljae206. doi: 10.1093.
     PubMed    
     
     
     
455. DU J, Dong C, Lin J, Lu X, et al
     MMP2hi Fibroblasts Regulate CD8+ T Cell Residency and Inflammation via CD100 in Psoriasis.
     Br J Dermatol. 2024 May 16:ljae205. doi: 10.1093.
     PubMed     Abstract available
     
     
     
456. HAMMAS K, Nardin C, Boyer S, Michel C, et al
     Incidence and trends of first basal cell carcinomas in France between 1980 and 2019: a regional population-based registry study.
     Br J Dermatol. 2024 May 15:ljae201. doi: 10.1093.
     PubMed     Abstract available
     
     
     
457. TANAHASHI K, Kono M, Yoshikawa T, Suzuki Y, et al
     Treating epidermolytic ichthyosis and ichthyosis with confetti with epidermal autografts cultured from revertant skin.
     Br J Dermatol. 2024 May 13:ljae193. doi: 10.1093.
     PubMed     Abstract available
     
     
     
458. RODRIGUEZ M, Rebollo-Gonzalez M, Frutos Diaz-Alejo J, Manso R, et al
     Mutational profiling of Primary Cutaneous CD4+ Small/Medium T-Cell Lymphoproliferative Disorders do not resemble nodal peripheral T-cell lymphomas with follicular helper T-cell phenotype.
     Br J Dermatol. 2024 May 13:ljae192. doi: 10.1093.
     PubMed    
     
     
     
459. PARRAGA SP, Feldman SR
     Insulin resistance and psoriasis.
     Br J Dermatol. 2024 May 13:ljae199. doi: 10.1093.
     PubMed    
     
     
     
460. BOITOR RA, Varma S, Sharma A, Odedra S, et al
     Diagnostic accuracy of autofluorescence-Raman spectroscopy for surgical margin assessment during Mohs micrographic surgery of basal cell carcinoma.
     Br J Dermatol. 2024 May 13:ljae196. doi: 10.1093.
     PubMed     Abstract available
     
     
     
461. PASSERON T, Reinhardt M, Ehst B, Weiss J, et al
     Secukinumab in adult patients with lichen planus: Efficacy and safety results from the randomised, placebo-controlled, proof-of-concept PRELUDE study.
     Br J Dermatol. 2024 May 13:ljae181. doi: 10.1093.
     PubMed     Abstract available
     
     
     
462. ROBINSON J, Kibbi N, Rajan N
     Redefine "benign": A misnomer in the context of patients with genetic skin tumour syndromes.
     Br J Dermatol. 2024 May 10:ljae185. doi: 10.1093.
     PubMed    
     
     
     
463. GUNTHER C
     IL-17 blockade by secukinumab was not effective in controlling lichen planus in a randomized controlled clinical trial.
     Br J Dermatol. 2024 May 8:ljae186. doi: 10.1093.
     PubMed    
     
     
     
464. ZHANG S, Ran M
     Deceptive Pigment Changes in Neoadjuvant Sonidegib Therapy for Basal Cell Carcinoma.
     Br J Dermatol. 2024 May 4:ljae187. doi: 10.1093.
     PubMed    
     
     
     April 2024
465. MALLBRIS MJ, Jia B, Zhao Y, Kahlenberg JM, et al
     Concomitant Moderate to Severe Cutaneous Lesions Have Marked Impact on Quality of Life in Patients with Active Systemic Lupus Erythematosus: A Cross-Sectional Insight from Two Phase 3 Randomised Clinical Trials in Adults.
     Br J Dermatol. 2024 Apr 30:ljae183. doi: 10.1093.
     PubMed    
     
     
     
466. HALIOUA B, Skayem C, Merhand S, Ben Hayoun Y, et al
     Long-term consequences on stigmatization and disease burden during adulthood among patients with childhood or adolescence-onset atopic dermatitis.
     Br J Dermatol. 2024 Apr 29:ljae176. doi: 10.1093.
     PubMed    
     
     
     
467. O'REILLY M, Paolino A, Pathmarajah P, Ferguson J, et al
     Dupilumab in Chronic Actinic Dermatitis: a retrospective case series.
     Br J Dermatol. 2024 Apr 24:ljae180. doi: 10.1093.
     PubMed    
     
     
     
468. LI Y, He Y, Yang F, Liang R, et al
     GSDME-mediated keratinocyte pyroptosis participates in the pathogenesis of psoriasis by promoting skin inflammation.
     Br J Dermatol. 2024 Apr 24:ljae179. doi: 10.1093.
     PubMed     Abstract available
     
     
     
469. NIELSEN JB, Kristiansen IS, Thapa S
     Increasing melanoma incidence with unchanged mortality: more sunshine, better treatment, increased diagnostic activity, overdiagnosis or lowered diagnostic threshold?
     Br J Dermatol. 2024 Apr 24:ljae175. doi: 10.1093.
     PubMed     Abstract available
     
     
     
470. LEEOLOU MC, Sarin KY, Fiorentino DF
     Filling the Prescription Gap: The Value of Community Support in Psoriasis Management.
     Br J Dermatol. 2024 Apr 18:ljae168. doi: 10.1093.
     PubMed    
     
     
     
471. HUANG D, Zhong X, Jiang Y, Kong L, et al
     Insulin Resistance Impairs Biological Agents Response in Moderate-to-Severe Plaque Psoriasis: Insights from a Prospective Cohort Study in China.
     Br J Dermatol. 2024 Apr 18:ljae147. doi: 10.1093.
     PubMed     Abstract available
     
     
     
472. 
     The association between vitamin D levels and psoriasis in people aged 40-79 years.
     Br J Dermatol. 2024;190:e54.
     PubMed    
     
     
     
473. 
     Effectiveness and safety of immunoadsorption in the treatment of pemphigus vulgaris and pemphigus foliaceus.
     Br J Dermatol. 2024;190:e53.
     PubMed    
     
     
     
474. 
     Predictors of response to treatment with biologics in people with moderate-to-severe psoriasis.
     Br J Dermatol. 2024;190:e55.
     PubMed    
     
     
     
475. 
     A novel strategy for the treatment of melanoma.
     Br J Dermatol. 2024;190:e51.
     PubMed    
     
     
     
476. 
     Practical guide for epidermolysis bullosa management in the first 4 weeks of life.
     Br J Dermatol. 2024;190:e52.
     PubMed    
     
     
     
477. 
     The Patient Benefit Index for topical treatment (PBI-TOP): a new questionnaire to assess the treatment goals and preferences of people with psoriasis.
     Br J Dermatol. 2024;190:e56.
     PubMed    
     
     
     
478. 
     Deciding on the final set of questions and groups of questions in the Patient-Reported Impact of Dermatological Diseases (PRIDD) tool.
     Br J Dermatol. 2024;190:e57.
     PubMed    
     
     
     
479. 
     Targeting malignant melanoma cells expressing the protein CD20 enhances BRAF-targeted treatment.
     Br J Dermatol. 2024;190:e58.
     PubMed    
     
     
     
480. 
     UK trends in work-related contact dermatitis caused by nickel, chromium and cobalt.
     Br J Dermatol. 2024;190:e59.
     PubMed    
     
     
     
481. 
     'Gene creams' for genetic diseases?
     Br J Dermatol. 2024;190:e50.
     PubMed    
     
     
     
482. PASSERON T
     A pledge for a better care and consideration of patients with vitiligo.
     Br J Dermatol. 2024;190:614-615.
     PubMed    
     
     
     
483. SAMPOGNA F, Piaserico S
     Deucravacitinib: is there still a place or a need for a new oral agent?
     Br J Dermatol. 2024;190:610-611.
     PubMed    
     
     
     
484. HASAN SB, Bates J, Cannings-John R, Collier F, et al
     Feasibility of daily pain measurement using text messages in hidradenitis suppurativa clinical trials; data from the THESEUS study.
     Br J Dermatol. 2024;190:775-777.
     PubMed    
     
     
     
485. KYUNG S, Woo S, Kim M, Lee H, et al
     Global burden of vaccine-associated alopecia, 1979-2023: a comprehensive analysis of the international pharmacovigilance database.
     Br J Dermatol. 2024;190:764-767.
     PubMed    
     
     
     
486. MOSS C
     Caring for babies born with epidermolysis bullosa.
     Br J Dermatol. 2024;190:608.
     PubMed    
     
     
     
487. RING HC, Thorsen J, Kirby B, Ingram JR, et al
     Long-term drug survival of adalimumab, infliximab, secukinumab and ustekinumab in hidradenitis suppurativa: a Danish nationwide cohort study.
     Br J Dermatol. 2024;190:769-771.
     PubMed    
     
     
     
488. FAKIH A, Tannous R, Lajnef M, Seneschal J, et al
     Stigma in vitiligo: associated factors and severity strata of the Patient Unique Stigmatization Holistic tool in Dermatology (PUSH-D) score.
     Br J Dermatol. 2024;190:712-717.
     PubMed     Abstract available
     
     
     
489. HASHIMOTO T, Yamagami J
     Development of a novel treatment for pemphigus and confirmation of its efficacy: a randomized controlled trial of protein A immunoadsorption therapy.
     Br J Dermatol. 2024;190:609.
     PubMed    
     
     
     
490. RIVERA S, Dehner K, Flood A, Dykstra C, et al
     Adverse healthcare experiences are correlated with increased time to diagnosis in women with vulvar inflammatory dermatoses: a retrospective cohort survey.
     Br J Dermatol. 2024;190:761-762.
     PubMed    
     
     
     
491. VAN BEEK N, Eming R, Reuss A, Zillikens D, et al
     Efficacy and safety of adjuvant immunoadsorption in pemphigus vulgaris and pemphigus foliaceus (IA-Pem Study): a multicentre randomized controlled trial.
     Br J Dermatol. 2024;190:657-667.
     PubMed     Abstract available
     
     
     
492. 
     The 2024 British Skin Foundation Research Awards are now available.
     Br J Dermatol. 2024;190:778.
     PubMed    
     
     
     
493. CHAIYABUTR C, Dawe R, Lesar A, Ibbotson SH, et al
     A retrospective comparison of early- and late-onset chronic actinic dermatitis: characteristics and management.
     Br J Dermatol. 2024 Apr 16:ljae101. doi: 10.1093.
     PubMed    
     
     
     
494. NASLUND-KOCH C, Skov L
     Shedding light on the smoke: Unraveling the impact of smoking cessation on psoriasis development.
     Br J Dermatol. 2024 Apr 15:ljae163. doi: 10.1093.
     PubMed    
     
     
     
495. PHILLIPS C, Russell E, McNiven A, McPherson T, et al
     A Qualitative Study of the Psychological Morbidity in Paediatric Survivors of Stevens-Johnson Syndrome and Toxic Epidermal Necrolysis.
     Br J Dermatol. 2024 Apr 12:ljae154. doi: 10.1093.
     PubMed    
     
     
     
496. BLANCHARD M, Morren MA, Busschots AM, Hauben E, et al
     Paediatric onset lymphomatoid papulosis: results of a multicentre retrospective cohort study, on behalf of the EORTC Cutaneous Lymphoma Tumours Group (CLTG).
     Br J Dermatol. 2024 Apr 10:ljae150. doi: 10.1093.
     PubMed     Abstract available
     
     
     
497. SIMPSON EL, Eckert L, Gadkari A, Brown TM, et al
     Evaluating the clinical utility of the Atopic Dermatitis Control Tool: measurement properties and agreement between patients' responses and clinicians' impressions of atopic dermatitis control.
     Br J Dermatol. 2024 Apr 9:ljae056. doi: 10.1093.
     PubMed    
     
     
     
498. JONES OT, Matin RN, Walter FM
     Using artificial intelligence-based technologies to support the diagnosis and early detection of melanoma in primary care.
     Br J Dermatol. 2024 Apr 9:ljae094. doi: 10.1093.
     PubMed    
     
     
     
499. CAO Q, Li M
     GLMN variants cause skin hyperpigmentation: a promising potential therapeutic target.
     Br J Dermatol. 2024 Apr 8:ljae149. doi: 10.1093.
     PubMed    
     
     
     
500. ROCCUZZO G, Calvao J, Dobos G, Morsia E, et al
     Cutaneous T-cell lymphoma care across Europe: insights from the Horizon Project.
     Br J Dermatol. 2024 Apr 5:ljae145. doi: 10.1093.
     PubMed    
     
     
     March 2024
501. KIM SR, Choi YG, Jo SJ
     Effect of smoking cessation on psoriasis vulgaris, palmoplantar pustulosis, and generalized pustular psoriasis.
     Br J Dermatol. 2024 Mar 27:ljae130. doi: 10.1093.
     PubMed     Abstract available
     
     
     
502. SANDER N, Stolzl D, Fonfara M, Hartmann J, et al
     Blockade of IL-13 signaling improves skin barrier function and biology in patients with moderate to severe atopic dermatitis.
     Br J Dermatol. 2024 Mar 26:ljae138. doi: 10.1093.
     PubMed     Abstract available
     
     
     
503. BENTZ P, Weisshaar E
     Biomarkers as key concepts in managing atopic dermatitis and psoriasis: Unlocking new ways of care for patient suffering from chronic hand dermatoses.
     Br J Dermatol. 2024 Mar 26:ljae127. doi: 10.1093.
     PubMed    
     
     
     
504. JOHNSON C, Liao W
     Food for thought: A comment on 'Breast-feeding decreases the risk of developing psoriasis through early adulthood'.
     Br J Dermatol. 2024 Mar 26:ljae135. doi: 10.1093.
     PubMed    
     
     
     
505. SOROKIN AV, Gelfand JM
     New Prospective Cohort Study and Mendelian Randomization Analysis Reveals a Link Between Psoriasis and Cardiovascular Risk Trough Elevated Plasma Triglycerides.
     Br J Dermatol. 2024 Mar 22:ljae129. doi: 10.1093.
     PubMed    
     
     
     
506. TALTY R, Richmond R, Micevic G
     Melanoma TIL therapy commences era of cell-based immunotherapies.
     Br J Dermatol. 2024 Mar 22:ljae126. doi: 10.1093.
     PubMed    
     
     
     
507. 
     Correction to: Circulating biomarkers are associated with disease severity of chronic hand eczema and atopic dermatitis.
     Br J Dermatol. 2024 Mar 22:ljae112. doi: 10.1093.
     PubMed    
     
     
     
508. STRANDMOE AL, Bremer J, Diercks GFH, Gostynski A, et al
     Beyond The Skin: B Cells in Pemphigus Vulgaris, Tolerance and Treatment.
     Br J Dermatol. 2024 Mar 20:ljae107. doi: 10.1093.
     PubMed     Abstract available
     
     
     
509. JIANG X, Yang C, Wang Z, Liang L, et al
     Loss-of-function variants in GLMN are associated with generalized skin hyperpigmentation with or without glomuvenous malformation.
     Br J Dermatol. 2024 Mar 15:ljae108. doi: 10.1093.
     PubMed     Abstract available
     
     
     
510. 
     AMBRA1 and loricrin as a test to identify low-risk early-stage melanoma.
     Br J Dermatol. 2024;190:e46.
     PubMed    
     
     
     
511. 
     Blood monitoring during psoriasis treatment with biologics.
     Br J Dermatol. 2024;190:e47.
     PubMed    
     
     
     
512. 
     Safety of bimekizumab over 3 years in patients with psoriasis.
     Br J Dermatol. 2024;190:e38.
     PubMed    
     
     
     
513. 
     International trends in the incidence of cutaneous squamous cell carcinoma and melanoma.
     Br J Dermatol. 2024;190:e40.
     PubMed    
     
     
     
514. 
     Skin barrier dysfunction drives skin inflammation via formylpeptide receptor 1.
     Br J Dermatol. 2024;190:e45.
     PubMed    
     
     
     
515. 
     2024 British Skin Foundation Small Grants are NOW AVAILABLE.
     Br J Dermatol. 2024;190:603.
     PubMed    
     
     
     
516. 
     Comparison of topical permethrin 5% and benzyl benzoate 25% for treating scabies.
     Br J Dermatol. 2024;190:e39.
     PubMed    
     
     
     
517. 
     Global consensus process to establish a core dataset for hidradenitis suppurativa registries.
     Br J Dermatol. 2024;190:e42.
     PubMed    
     
     
     
518. 
     The relationship between paediatric eczema and cognition.
     Br J Dermatol. 2024;190:e41.
     PubMed    
     
     
     
519. 
     A guide to using the core outcome set for eczema.
     Br J Dermatol. 2024;190:e44.
     PubMed    
     
     
     
520. GARMAN KA, Thoreson N, Strong J, Hallaert P, et al
     Mycophenolate mofetil inhibits Merkel cell carcinoma growth.
     Br J Dermatol. 2024;190:593-595.
     PubMed     Abstract available
     
     
     
521. CORNMAN HL, Whang KA, Ma E, Aggarwal P, et al
     Severity, impact on quality of life and mental health burden of pruritus in prurigo nodularis: a cross-sectional study of a diverse patient cohort.
     Br J Dermatol. 2024;190:571-572.
     PubMed    
     
     
     
522. CLAIRE FULLER L, Sunderkotter C
     Scabies therapy update: Should 25% benzyl benzoate emulsion be reconsidered as a first-line agent in classical scabies?
     Br J Dermatol. 2024;190:459-460.
     PubMed    
     
     
     
523. NIELSEN W, Drucker AM
     The need and benefit of the Harmonising Outcome Measures for Eczema user's guide.
     Br J Dermatol. 2024;190:462-463.
     PubMed    
     
     
     
524. XIE W, Kong X, Zheng H, Mei H, et al
     Rapid emergence of recalcitrant dermatophytosis caused by a cluster of multidrug-resistant Trichophyton indotineae in China.
     Br J Dermatol. 2024;190:585-587.
     PubMed    
     
     
     
525. NANDA A, Chang YH, Cheng HC, Lai IT, et al
     Autosomal recessive plantar keratoderma with ragged periungual hyperkeratosis caused by a homozygous missense variant in KRT16.
     Br J Dermatol. 2024;190:588-590.
     PubMed    
     
     
     
526. COWPER R
     For itch and insanity.
     Br J Dermatol. 2024;190:568.
     PubMed    
     
     
     
527. BARLOW R, Ahmed A, Fellows J, Goulding J, et al
     Assessing and managing the mental health of people with vitiligo: a UK-wide consultation exercise.
     Br J Dermatol. 2024;190:574-576.
     PubMed    
     
     
     
528. MEYERSBURG D, Hoellwerth M, Brandlmaier M, Handisurya A, et al
     Comparison of topical permethrin 5% vs. benzyl benzoate 25% treatment in scabies: a double-blinded randomized controlled trial.
     Br J Dermatol. 2024;190:486-491.
     PubMed     Abstract available
     
     
     
529. MOSCARELLA E, Di Brizzi EV, Alpi P, Arcelli A, et al
     Indications for adjuvant radiotherapy in high-risk cutaneous squamous cell carcinoma with clear margins: a Delphi consensus.
     Br J Dermatol. 2024;190:578-579.
     PubMed    
     
     
     
530. DONHAUSER T, Gabes M, Ozkan E, Masur C, et al
     What do Hyperhidrosis Quality of Life Index (HidroQoL(c)) scores mean? Transferring science into practice by establishing a score banding system.
     Br J Dermatol. 2024;190:519-526.
     PubMed     Abstract available
     
     
     
531. WAINMAN HE, Chandran NS, Frew JW, Garg A, et al
     Global consensus process to establish a core dataset for hidradenitis suppurativa registries.
     Br J Dermatol. 2024;190:510-518.
     PubMed     Abstract available
     
     
     
532. GEORGE CD, Lee T, Hollestein LM, Asgari MM, et al
     Global epidemiology of actinic keratosis in the general population: a systematic review and meta-analysis.
     Br J Dermatol. 2024;190:465-476.
     PubMed     Abstract available
     
     
     
533. NALDI L, Cassalia F
     Actinic keratosis epidemiology: the good, the bad and the ugly.
     Br J Dermatol. 2024;190:457-458.
     PubMed    
     
     
     
534. OYESIKU L, Dlova N, Ahmed S, Owen DR, et al
     Inclusive and equitable language for skin colour in the British Journal of Dermatology: acknowledging our past and laying the foundations to move forward.
     Br J Dermatol. 2024 Mar 13:ljae064. doi: 10.1093.
     PubMed    
     
     
     
535. AALA WJF, Hou PC, Hong YK, Lin YC, et al
     Dominant dystrophic epidermolysis bullosa is associated with glycolytically active GATA3+ Th2 cells which may contribute to pruritus in lesional skin.
     Br J Dermatol. 2024 Mar 13:ljae110. doi: 10.1093.
     PubMed     Abstract available
     
     
     
536. 
     Correction to: Malignancy risk in patients with atopic dermatitis: a population-based cohort study.
     Br J Dermatol. 2024 Mar 12:ljae093. doi: 10.1093.
     PubMed    
     
     
     
537. CANTISANI C, Taliano A, Longo C, Bortone G, et al
     Dynamic Optical Coherence Tomography and Reflectance Confocal Microscopy of Basal Cell Carcinoma of the Nipple-Areola Complex.
     Br J Dermatol. 2024 Mar 12:ljae104. doi: 10.1093.
     PubMed    
     
     
     
538. ARMATO U, Dal Pra I
     Discovering skin-rejuvenating matrikines - a basic and applied Dermatology new frontier.
     Br J Dermatol. 2024 Mar 12:ljae100. doi: 10.1093.
     PubMed    
     
     
     
539. CHEN GF, Xu S, White MA, Cohen JM, et al
     Association between atopic dermatitis and eating disorders: a cross-sectional study in the All of Us Research Program.
     Br J Dermatol. 2024 Mar 11:ljae103. doi: 10.1093.
     PubMed    
     
     
     
540. RA AG, Littlewood Z, Barton A, Keevil B, et al
     The use of serum methotrexate level as an assessment of biochemical drug adherence in psoriasis.
     Br J Dermatol. 2024 Mar 8:ljae096. doi: 10.1093.
     PubMed    
     
     
     
541. REHBINDER EM, Warnberg Gerdin S, Hoyer A, Bradley M, et al
     Frequent oil-baths and skin barrier during infancy in the PreventADALL study.
     Br J Dermatol. 2024 Mar 6:ljae091. doi: 10.1093.
     PubMed     Abstract available
     
     
     
542. EL HACHEM M, De Marco R, Soria de Francisco JM, Audouze A, et al
     Ichthyosis: multinational European study on patient characteristics and body sites involved with impact on quality of life.
     Br J Dermatol. 2024 Mar 1:ljae082. doi: 10.1093.
     PubMed    
     
     
     February 2024
543. RIBERO S, Quaglino P, Roccuzzo G
     Unveiling cutaneous adverse events and prognosis in immunotherapy for melanoma and squamous cell carcinoma.
     Br J Dermatol. 2024 Feb 29:ljae092. doi: 10.1093.
     PubMed    
     
     
     
544. RAMESSUR R, Dand N, Langan SM, Saklatvala J, et al
     Defining disease severity in atopic dermatitis and psoriasis for the application to biomarker research- an inter-disciplinary perspective.
     Br J Dermatol. 2024 Feb 29:ljae080. doi: 10.1093.
     PubMed     Abstract available
     
     
     
545. GREVE AM, Wulff AB, Bojesen SE, Nordestgaard BG, et al
     Elevated plasma triglycerides increase risk of psoriasis: A cohort and Mendelian randomization study.
     Br J Dermatol. 2024 Feb 27:ljae089. doi: 10.1093.
     PubMed     Abstract available
     
     
     January 2024
546. SAAD R, Duipmans J, Yerlett N, Plevey K, et al
     Neonatal Epidermolysis Bullosa: a clinical practice guideline.
     Br J Dermatol. 2024 Jan 4:ljae006. doi: 10.1093.
     PubMed     Abstract available
     
     
     December 2023
547. FORKEL S, Schubert S, Corvin L, Heine G, et al
     Contact allergies to dental materials in patients.
     Br J Dermatol. 2023 Dec 20:ljad525. doi: 10.1093.
     PubMed     Abstract available
     
     

Thank you for your interest in scientific medicine.

AMEDEO Dermatology is free of charge.